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INTRODUCTION 
In The Netherlands about 300 deaths per year are due to cervical 
cancer and about 1200 new cases of invasive cervical cancer are diag-
nosed every year (1-2) The incidence of cervical cancer in The 
Netherlands is comparable with the incidence in other Western coun-
tries and relatively low compared with the incidence m parts of Latin 
America (3) 
The etiology of cervical cancer was subject of numerous studies 
Like other cancer types, the risk of cervical cancer increases with 
age Women with an early age at f i rst sexual intercourse and women 
with a history of multiple sexual partners are more likely to develop 
cervical neoplasia (4-8) Also the sexual behaviour of the male part-
ner seems important and indicates the infectious and venereal trans-
mission of cervical cancer (9) Human papillomavirus, a sexually 
transmitted agent, is increasingly implicated in the pathogenesis of 
cervical cancer (10) Recently it is suggested that cigarette smoking 
plays a part m one of the earlier stages of cervical carcinogenesis 
(11) Nicotine and cotmme can be detected m the uterine cervix of 
cigarette smokers and could possibly have a genotoxic effect on the 
cervical epithelium (12) 
It is self-evident that primary prevention of cervical cancer on basis 
of this information is practically impossible Therefore early-detection 
programmes have been developed George Papanicolaou (1883-1962) 
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proved the usefulness of exfoliative cytology in the diagnosis of early 
uterine cancer. He performed his studies between 1925 and 1943 and 
gradually the "Paptest" was adopted on a worldwide basis. After 
promising results of cervical screening in other countries, in The 
Netherlands population screening was introduced in 1976 in three pilot 
regions (13-16). 
This thesis deals with several aspects of the evaluation of one of the 
three pilot programmes i.e. the one in Nijmegen region. In order to 
be able to interpret the change in mortality after introduction of the 
screening programme trends in cervical cancer rates in The Nether-
lands for the past five decades are described in Chapter 1. To esti-
mate the effect of changes in therapy in the last 15 years on 
mortality figures a survival analysis was performed. Survival rates 
of women with invasive cervical cancer in the period 1970-1985 are 
presented in Chapter 2. 
Chapter 3 gives a description of the cervical screening programme in 
the region of Nijmegen. In this chapter a summary is given of the 
organisation of the screening programme and of attendance, referral 
and detection rates. 
The main aspect in the evaluation is the effectiveness of population 
screening for cervical cancer. The effectiveness of the Nijmegen pro-
gramme was studied in two ways. In Chapter 4A the results of a 
population-based case-control study are described. In this study, 
participation in a screening programme was reviewed as a preventive 
factor for invasive cancer. 
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The effectiveness of the screening programme was also evaluated by 
determining changes in the incidence rate of invasive cancer of the 
uterine cervix (Chapter 4B). 
An important aspect of the effectiveness of a screening programme is 
the validity of the screening test which is discussed in Chapter 5. 
Chapter 5A deals with the false negative rate in cervical cytology and 
Chapter 5B with screening errors. 
In Chapter 6 all aspects of screening are briefly reviewed in the light 
of public health policy. 
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CHAPTER 1 
CERVICAL CANCER MORTALITY IN THE 
NETHERLANDS* 
Yolanda van der Graaf MD, Gerhard A Zielhuis MSc, PhD, Peter G 
Vooijs MD, PhD 
Summary 
In this study cervical cancer mortality figures for the period 
1936-1983 were evaluated. For the period 1950-1981 trends m age-
specific rates were analysed by separating the variations attributable 
to age at death, period of birth and perioH of death. 
Cervical cancer mortality decreased since 1960 and the decline was 
more rapid from about 1975 The organized screening, which started 
m 1976 could be responsible for the acceleration in the decline, but 
since the decline was already evident before screening commenced, 
other factors must play a role It seemed likely that a fall in inci-
dence or an improvement of early diagnosis were responsible for the 
decline The cohort analysis showed an increased risk for younger 
age groups but since the observations were derived from one f ive-
year age group no firm conclusions about future trends can be made 
yet. 
*Submitted 
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Introduction 
Reduction of the number of deaths due to cervical cancer is one of 
the mam goals of cervical cancer screening programmes. Lack of 
randomized trials prevents a conclusive evaluation of the effect of 
screening and since cervical screening is widely accepted as a useful 
practice such a tr ial will never be performed. 
In several countries cervical cancer mortality declined some years 
after the start of the screening programmes (1-8). The role of cer-
vical screening m this decline is debated by some people, because 
cervical mortality already started to decline prior to the start of the 
screening programmes and furthermore was also observed m countries 
where cervical screening was not common (9) 
In The Netherlands population screening started in 1976, relatively 
late in comparison with other countries. For this reason trends m 
cervical cancer mortality rates cannot be the consequence of the cer-
vical screening programmes. In this study mortality figures for the 
period 1936-1983 are evaluated against the background of a possible 
"natural" trend in cervical cancer mortality. 
Populations and Methods 
Data on the number of deaths due to cervical cancer as well as popu-
lation data were derived from the Central Bureau of Statistics (10). 
This institution compiles the causes of death according to ICD-
agreements. The data used in this study are based on death cert i f i -
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cates which state cervical cancer as primary cause of death. Age-
specific mortality figures were available for the calendar period 
1936-1983. 
Mortality rates were estimated with age-specific mid-year population 
numbers (age 25 and o v e r ) . Comparisons were based on age-adjusted 
mortality rates and on mortality ratios. Tests of homogeneity were 
performed and 95% confidence limits were calculated (11 ) . Graphs 
were smoothed by means of spline functions (12 ) . For the calendar 
period 1950-1981 we were able to perform a cohort analysis. The log-
linear model as described by Barrett was used to separate the varia-
tions attributable to age at death, period of birth and period of death 
(13) . Each age-specific death rate was regarded as the product of 
three numbers - an age value, a period of birth value, and a period 
of death value. Each cohort was characterised by its central year of 
b i r th . Since knowledge of any two of age at death, period of b i r t h , 
and period of death neccessarily implies knowledge of the t h i r d , these 
three factors are not statistically independent and some assumptions 
have to be made. We assumed that the period of death factor for 
1977-1981 was zero and the factors for the period of birth 1881-1885 
and 1886-1891 were zero. The model permits only conclusions about 
changes in trends not about linear t rends. Cohort values relating to 
the earliest and latest years of birth were based on fewer age-specific 
death rates than the central cohorts. Thus in Figure 5 cohort values 
shown as points on the extreme left and right were derived from one 
f ive-year age group, those adjacent from two, and so on. This means 
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that the extreme points are statistically less reliable than the central 
ones. The extreme right ones were based on recent death rates in 
young women and may give an important clue for the future t rend. 
Results 
Crude mortality rates are summarized in Table 1 . The crude rate is 
lower in the decade after world war II and in the past 15 years. 
Table 1: 
Cervical cancer mortality rates subdivided for 
and in absolute numbers per year (mean 
Calendar period Mortality per 
100.000 woraan-
1936-1939 •* 12.3 
1940 1944 10.6 
1945-1949 9.9 
1950 1954 13.2 
1955-1959 12.4 
1960-1964 12.4 
1965-1969 11.7 
1970-1974 8.9 
1975-1979 9.0 
1980-1984 7.0 
* calendar period of 4 years only 
of the 
years 
10 calendar periods 
10 years period) 
Mean number of 
deaths per year 
292 
267 
266 
332 
388 
413 
415 
341 
375 
315 
Crude rates are difficult to interpret since changes in age distr ibu-
tion can be responsible for t rends. Mortality rates for 5-year age 
groups are displayed in frequency blocks in Figure 1 . Mortality 
below 35 is low during the entire period. 
In all the other age groups a dip at the end of world war II and 
immediately afterwards is visible and rates are declining since 1960. 
The decline is most evident in the age groups 35 through 54 years. 
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Figure 1 : Cerv ical cancer mor ta l i ty per 100.000 women years in The 
Nether lands 1936-1983 accord ing to age g roup and calendar 
pe r iod . 
To adjust f o r age, i nd i rec t l y age-s tandard ized mor ta l i t y rat ios 
(SMR's) were calculated f o r the per iod 1936-1983. The mor ta l i t y rates 
of the Dutch sum populat ion 1936-1983 were used as a s t a n d a r d . To 
check if a t r e n d in mor ta l i t y rates was simi lar in all ages, tests of 
homogeneity were done in each 5-year age g r o u p . In some years th is 
test shows s ign i f i can t resu l t s , bu t one should not pay too much 
at tent ion to th is f i n d i n g as the s ign i f i cant resu l t was always the con-
sequence of a dev iant mor ta l i ty rate in one age g r o u p . Mor ta l i t y rates 
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are based on small numbers of cervical deaths in each age group. 
The calculated SMR's plus the corresponding 950o confidence limits are 
graphed in Figure 2. After this procedure the dip during world war 
II and the steep decline since 1960 are even more evident. 
Figure 2: Standardized mortality ratios and 95o confidence intervals 
for cervical cancer in The Netherlands 1936-1983. 
In Figure 3 age-specific mortality figures according to period of bir th 
are graphed. Mortality is decreasing in the older bir th cohorts. The 
bir th cohorts from 1911 and 1916 show higher age-specific mortality 
rates than the cohorts born before. The cohorts of 1926 and 1931 
show a strong decline in age-specific mortality. 
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Figure 3: Age specific mortality rates according to year of b i r th . 
Mortality during 1950-1981. 
In Figure 4 and 5 the age, time and cohort-factors are graphed. In 
Figure 4 the age value is plotted against age at death. Mortality 
increases with increasing age. In Figure 5 cohort values are plotted 
against central year of b i r th . If the cohort values are interpreted in 
terms of birth there was an increase until the 1926 cohort. After this 
there was a decrease t i l l the 1941 cohort. The cohort value of the 
youngest cohort increases but this value is based on only one f ive-
year age group. There is a gradual decline in the period of death 
values. 
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Figure 4: Age values. M o r t a l i t y d u r i n g 1950-1981. 
0 8 S 
0.0 • 
1886 І Щ ¡906 ¡916 ¡ « 6 ¡93* ÎM6 
year of b i r th 
51-56 57-61 62-66 67-71 7i-76 77-81 
year of death 
Figure 5 ; Cohor t and per iod of death va lues . Mor ta l i t y d u r i n g 
1950-1981. 
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Discussion 
Organized screening on a large scale started m The Netherlands in 
1976 Before that year there was one pilot study m the city of 
Utrecht a id adjacent communities (14) Before 1970 cervical screening 
was rare and a smear was made only for medical reasons The effect 
of screening on mortality rates can be expected from about 10 years 
after the introduction of screening Possibly the substantial accelera-
tion m the mortality decline at the beginning of the 1980 s could be 
due to the early detection programmes, but it is not possible that the 
mortality decline since the early 1960's is the result of organized 
screening Therefore other factors must play a role m the decline 
Such factors may be related to either registration errors, a fall m the 
incidence of cervical cancer, improved therapy or a combination of 
these 
Percy et al compared the hospital diagnosis with the diagnoses given 
in the death certificates (15) As far as cervical cancer is concerned, 
80 percent of these cancers were correctly reported on the death cer-
tificates as cervical cancers, whereas 10 percent was reported as can-
cer of the corpus Even when the accuracy of death certificates m 
The Netherlands would be less, it is not likely that it became even 
worse m recent years The dip at the end and immediately after 
world war II is most probably due to registration failures 
Prior to 1970 about SO'i of all deaths due to cervical cancer were 
reported on the death certificates as cancer of the uterus which was 
not fur ther specified, but after 1970 registration improved (10) When 
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correcting for this relatively large number of not fur ther specified 
cancers of the uterus the decline in mortality rates after 1960 would 
even be more steep than is shown m Figure 2. 
If the fall in mortality should reflect a fall in incidence, what factors 
could have produced it7 In studies about the etiology of cervical can-
cer the most significant risk factors are early sexual intercourse and 
promiscuity (16-20). There is no evidence that m the last decade 
women have begun to delay f i rst intercourse or have become less 
promiscuous. The hypothesis that cervical cancer is a venereal dis-
ease, is not yet supported by mortality trends in The Netherlands. In 
England Osmond concluded from the results of a cohort study that the 
women born after 1945 were at higher risk for cervical cancer (21). 
In the cohort analysis of Dutch mortality data for cervical cancer an 
increased risk for younger age groups was found. 
However one has to keep in mind that mortality rates for the women 
born after 1945 are only available ti l l they have a maximum age of 40 
years. Therefore firm conclusions about a significant change m mor-
tality rates in women born after world war II are not yet possible. 
Contrary to what has been reported for the United Kingdom, no sig-
nificant increase in morbidity from cervical cancer in women below 35 
years of age has become evident in The Netherlands (22). 
A possible explanation for the fall m incidence is improved genital 
hygiene, which might reduce the risk of an etiologic infective agent 
being transmitted. 
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Apart from a decrease in incidence, the fall in mortality rates could 
be due to more effective treatment. A slight improvement in therapy 
has been documented but this change is still too small to account for 
the rather dramatic decline in cervical mortality (23 ) . 
Probably the diagnosis of invasive cancer in a less advanced stage 
could also be of influence. Since there is no national cancer registry 
in The Netherlands, data about the incidence and the distribution of 
the different clinical stages of invasive cervical cancer are not avail -
able to support this view. 
The rising hysterectomy rate could also be an important cause for the 
decline in cervical cancer mortality, but Lyon and Miller showed that 
the increase in hysterectomy rates in the United States and Canada 
was not sufficient to explain the decreases in mortality rates which 
have occurred during the same period in cancers of the cervix 
(24-26) . In The Netherlands the increase in the number of hysterec-
tomies started in the seventies. Bosman et al showed that over the 
years 1975-1978 only 6% of the decrease of mortality due to cervical 
cancer can be attr ibuted to the increased frequency of the hysterec-
tomy rate (27 ) . It is likely that , if the number of hysterectomies 
continues to rise at the present state, the impact on the decline in 
cervical mortality rates will become more important. 
Analysis of Dutch cervical mortality rates showed a decline in the 
number of deaths due to cervical cancers. Neither cytological screen-
ing nor an increased rate of hysterectomies nor improved therapy can 
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be considered responsible for this decline; a fall in incidence because 
of better genital hygiene or an improvement of early diagnosis seems 
the most reasonable explanation. Til l now no data are available to sort 
out which one of these explanations is responsible for the ongoing 
decline in cervical cancer mortality. 
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CHAPTER 2 
CERVICAL CANCER SURVIVAL IN NIJMEGEN REGION. 
THE NETHERLANDS, 1970-1985* 
Yolanda van der Graaf MD, Petronella GM Peer MSc, Gerhard A Ziel-
huis MSc, PhD, Peter G Vooijs MD, PhD 
Summary 
For 359 women, diagnosed between 1970 and 1985 with invasive cervi-
cal cancer, survival rates were computed The 5-year survival rate 
for the entire group was 67° Survival was better in the period 
1976-1980 Extension of the tumor and age at diagnosis were important 
prognostic factors. The effects of clinical stage, age at diagnosis 
and year of diagnosis were studied simultaneously with the propor-
tional hazards model. The hazard rate increased with increasing age 
and increasing clinical stage Only m case of MB tumors year of 
diagnosis had effect on survival For the other clinical stages there 
was no significant effect on survival of year of diagnosis. 
Introduction 
Cervical mortality rates are declining in several Western countries 
(1) In The Netherlands cervical cancer mortality decreased since 
^Submitted 
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1962 Since cervical cancer screening programmes in The Netherlands 
did not start before 1976, cervical screening cannot be an explanation 
for this decline 
A fall m incidence of cervical cancer or a shift towards diagnosis of 
invasive cervical cancer m a less advanced stage seems the best 
explanation for this "natural" decline However improvements of ther-
apy with a better patient survival could also be at least for some part 
responsible for the decrease m mortality from cervical cancer. Ketting 
computed survival rates for all patients with invasive cancer of the 
uterine cervix treated in a large municipal hospital for the calendar 
period 1950-1979 (2) He reported an improvement in therapeutic 
results m patients with stage I, II and III of cervical cancer. He 
proposed the change m the treatment scheme in the period 1961-1969 
as an explanation for the decrease m mortality. In this study we 
evaluated the survival of cervical cancer patients in Nijmegen region 
in the calendar period 1970-1985 m order to investigate improvement 
in therapeutic results in the last 15 years. 
Patients and Methods 
Population screening for cervical cancer started m 1976 m three pilot 
regions in The Netherlands In these regions a quarter of the Dutch 
population is l iving All women aged 35 through 54 were invited every 
three years for a cervical smear. Apart from the screening pro-
gramme an increasing number bf smears is made by general practit ion-
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ers and gynecologists. In the region of Nijmegen (about 750.000 
inhabitants) data on the incidence of invasive cervical cancer were 
available from the local cancer registry which has been kept since 
1970 ( 3 ) . From the files of all pathology laboratories in the region all 
women were registered with a histological diagnosis of microinvasive 
or invasive cancer of the uterine cervix. If a histological diagnosis 
was made in a pathology laboratory outside the region this diagnosis 
will not become available for registration but such cases were excep-
tions. 
Items registered were age at diagnosis, date of diagnosis and clinical 
stage of the cervical cancer. Classification of the extension of the 
tumor is done according to the FIGO classification ( 4 ) . 
All diagnoses of cervical cytological smears made in the screening 
programme as well as by general practitioners and gynecologists were 
added to the registry of histological diagnoses. 
All patients known with cervical cancer were followed for vital status 
with the help of the registrar's offices and the Central Bureau of 
Statistics. For a few cases this information was obtained directly 
from gynecologists and general practitioners. Since at the time the 
study was terminated several patients were alive and other patients 
were lost to follow up, survival curves were computed according to 
the technique of Kaplan-Meier ( 5 ) . Death from other causes is con-
sidered censoring. The standard errors of the estimated survival 
rates were computed according to the Greenwood formula ( 6 ) . To 
test the equality of survival curves for different groups, the Mantel 
log-rank test was used ( 7 ) . 
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In order to asses the effect of clinical stage of disease, age at 
diagnosis and year at diagnosis simultaneously we used the propor-
tional hazards model according to Cox ( 8 ) . 
Results 
During the study period 378 women were diagnosed with invasive cer-
vical cancer. Of 10 women no follow up data could be traced and of 
9 women clinical stage of the tumor remained unknown. These women 
were left out of the analysis. In Table 2 clinical stage distribution 
according to age and point of time at diagnosis for the remaining 359 
women is summarized. 
Table 2: 
Clinical s 
Age 
< 54 
Ì 55 
tage distribution according 
IA 
N 
71(35%) 
13(8%) 
co age and 
Clinical stage 
IB 
N 
54(26%) 
28(18%) 
IIA 
N 
18(9%) 
12(8%) 
IIB 
N 
31(15%) 
51(33%) 
calendar 
III 
N 
23(11%) 
42(27%) 
period 
IV 
8(4%) 
8(5%) 
Total 
205 
154 
Calendar 
period 
1970-1975 
1976-1980 
1981-1985 
27(19%) 
38(28%) 
19(25%) 
35(24%) 
25(18%) 
22(29%) 
13(9%) 
14(10%) 
3(4%) 
41(28%) 
28(20%) 
13(17%) 
23(16%) 
27(20%) 
15(19%) 
6(4%) 
5(4%) 
5(6%) 
145 
137 
77 
1 
The Kaplan-Meier survival curve for the total group of women is dis-
played in Figure 6. Five-year survival was calculated at 67.4% (stan-
dard error 2.6%). This plot illustrates that 5-year survival is a good 
Screening for cervical cancer page 25 
parameter for survival since only a few women die from cervical can­
cer after the f i f th year. 
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Figure 6: Survival curve of women with cervical cancer. Region of 
Nijmegen, The Netherlands, 1970-1985. 
Table 3 shows the effect of extension of the tumor, age and calendar 
period on 5-year survival. 
Table 3: 
Survival rates according to clinical stage, 
5-year survival 
5-year survival 
5-year survival 
Clinical stage (FIGO) 
IA IB IIA 
97% 77% 83% 
Age group 
<35 35-54 
91% 72% 
Calendar period 
1970-1975 
62% 
age 
1976 
72% 
group 
IIB 
55% 
-1980 
and calendar period 
III IV 
36% 11% 
55-70 >70 
60% 34% 
1981-1985 
67% 
I 
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In general women with less advanced stages have a better survival 
Exceptions are women with cervical cancers in clinical stage HA. 
These women had a better survival then women with clinical stage IB 
tumors, although not significant (Mantel log-rank test p=0.52). Ml 
other pairwise comparisons yielded significant results with the log-
rank test. Survival curves for each stage are plotted in Figure 7. 
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Figure 7: Survival curves of women with cervical cancer according to 
clinical stage Region of Nijmegen, The Netherlands, 
1970-1985 
Survival rates differed also between age groups as is shown m Table 
3. Survival was better m younger women. Although survival rates 
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differed significantly between the three calendar periods, they do not 
show a t rend. To study the effect of clinical stage, age at diagnosis 
and year of diagnosis simultaneously, these three factors were incor-
porated into the proportional hazards model according to Cox. This 
multivariate regression model takes into account the correlation 
between the three factors. 
Because it was unlikely that for the same tumor stage, improvement of 
therapy differed for different ages and that the effect of age on sur-
vival was different for the various clinical stages, we did not take 
into account interaction of age with year of diagnosis and tumor 
stage. It could be, however, that only for some clinical stages ther -
apy improved in the course of time For that reason, age at diagno-
sis, clinical stage, year at diagnosis and the interactions of clinical 
stage and year of diagnosis were entered m the model Only in cl ini-
cal stage IIB the effect of year of diagnosis was significant and so m 
the final model age at diagnosis, clinical stage and the effect of year 
at diagnosis m clinical stage MB were entered (Table 4) 
Table 4 
Regression coefficients for 
effect of year of diagnosis 
model 
Variables 
Age at diagnosis 
reference age 50 
Year of diagnosis 
in stage IIB 
reference 1975 
Clinical stage IA 
reference IB IIA 
IIB 
III 
IV 
clinical stage, 
in stage IIB in 
Regression 
coefficients 
0.018 
-0.10 
-2.30 
-0 33 
0 65 
1 26 
2.20 
age 
Cox 
Standard 
error 
0 0078 
0 0467 
0 7421 
0 4635 
0 2820 
0 2762 
0 3716 
at diagnosis and the 
s proportional hazards 
Quotient 
2 
2 
3 
0 
2 
4 
5 
34 
20 
10 
70 
32 
59 
92 
P-value 
one-sided 
0.0097 
0 0137 
0.0009 
0 2408 
0 0102 
0 0000 
0.0000 
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Increasing age and increasing clinical stage gave a significant higher 
mortality. For stage IB and I IA , however, there was no significant 
difference in survival . For women with a stage MB tumor survival 
improved in the course of years. Comparison of the different surviv-
al curves predicted from the model with the Kaplan-Meier survival 
estimates revealed a good f i t . 
Discussion 
The overall 5-year survival rate calculated in this study population is 
comparable with survival rates reported by others (2 9 10). The 
"extension" (clinical stage) of the tumor seems the best predictor of 
survival . 
Less advanced clinical stages with better survival were more f re -
quently diagnosed in young women. Only part of these better survival 
rates in the youngest age groups can be explained by this phenom-
enon since after correcting for clinical stage the effect of age 
remained. Only for women with a stage MB tumor survival improved 
significantly during the last 15 years. Survival rates for these women 
became in the 1980's as high as for women with IB and MA tumors, 
while in the period before 1980 5-year survival was calculated at 46%. 
This gain in life expectancy must be the result of improvement in 
radiotherapeutic treatment since all women with a stage MB tumor 
were treated with radiation therapy with curative intent. This finding 
is comparable with the results described by Ketting ( 2 ) . In that 
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study 5-year survival was 40% for stage I IB patients in the period 
1961-1969 and 70% in the period 1970-1974 and comparable with the 
5-year survival rate in stage HA patients. The 5-year survival rate 
for cases with a IB tumor was in our study somewhat lower than 
reported by Ketting ( 2 ) . In his study the 5-year survival for these 
cases was 84% in the period 1970-1974. Possibly this difference can 
be explained by the fact that the study populations were not compa-
rable. Our study was population-based and the women were treated in 
the regional hospitals and in one university hospital, while in the 
study of Ketting all women were treated in a center. 
The population screening led to a decrease of the incidence of inva-
sive cervical cancer. In the period prior to the population screening 
programme (1970-1976) the yearly incidence of invasive cervical can-
cer was 18.6 per 100.000 in women aged 35 through 54 years. 
During the f i rst screening period the incidence was 21.5 per 100.000 
women, in the second screening period 9 .0 per 100.000 women and in 
the third screening period 3.3 per 100.000 women. The incidence of 
invasive cancer among women older than 54 years, who were not 
included in the cervical cancer screening programme, showed a 
decline 6 years after the start of the programme. This can be 
explained by the increasing percentage of women in this age group 
who in previous years, were eligible for the cervical cancer screening 
programme and hence received treatment when a preinvasive lesion 
was discovered. 
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In the course of 15 years a shift to more favourable clinical stages 
became evident. This shift to less advanced stages of cervical cancer 
at diagnosis and the improvement of therapy for women with a stage 
MB tumor are responsible for a better overall survival . For the oth-
er clinical stages survival did not improve significantly during the 
last 15 years. 
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CHAPTER 3 
POPULATION SCREENING FOR CERVICAL CANCER IN 
THE REGION OF NIJMEGEN, THE NETHERLANDS 
1976-1985* 
Yolanda van der Graaf MD, Peter G Vooijs MD, PhD, Gerhard A 
Zielhuis MSc, PhD 
Summary 
In this study the results of 9-year cervical screening in the region of 
Nijmegen, The Netherlands are presented. 
All women aged 35 through 54, were invited every three years for a 
cervical smear. Overall attendance rates were 74%, 67% and 63% at 
f i rs t , second and th i rd screening respectively. The number of histo-
logically confirmed severe epithelial abnormalities discovered in women 
who were screened for the f irst time was 3.8 per thousand smears, 
1.0 per thousand in women who were screened twice and 0.7 per 
thousand in women who were screened three times in the programme. 
Three years after the start of the screening programme the incidence 
of invasive squamous cell cancer started to decline in the women aged 
35 through 54 years. On the basis of the results of this study we 
may conclude a screening policy with an interval of three years to be 
a safe procedure. Whether this interval is the most efficient cannot be 
*Gynecologic Oncology In Press 
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concluded. We have the impression that an interval of four to six 
years may lead to comparable results. 
Introduction 
In The Netherlands 300 deaths per year are due to cervical cancer 
and about 1200 new cases of invasive cervical cancer are diagnosed 
every year. The incidence of cervical cancer in The Netherlands is 
comparable with the incidence in other Western countries and relative-
ly low compared to other cancer types. After promising results of 
cervical screening in other countries (1-4) cervical screening was ini-
tiated in The Netherlands in 1976. 
Screening was initiated by the government as pilot projects in dif fer-
ent regions to evaluate the effectiveness of screening for cervical 
cancer and to assess the best organisation scheme for a nationwide 
screening programme. When screening should prove to be effective it 
should be implemented in general practice. 
Since politically it proved to be unacceptable to offer this screening 
facility to a part of the population only, few years after the start of 
the screening programme in the pilot regions, screening was intro-
duced in the entire country. 
Effectiveness should be assessed by comparing morbidity and mortality 
figures in the three pilot regions with the other regions in The Neth-
erlands. 
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In this study we present the results of 9-year cervical screening in 
one of the pilot regions, the city of Nijmegen and its environments. 
Populations and methods 
The entire screening programme comprised nine years subdivided in 
three periods of three years each Every three years all women aged 
35 through 54 were invited for a cervical smear. The invitations were 
sent by the registrar's offices of the 62 municipalities which part ici-
pated m the screening programme The programme got quite some 
publicity and in the local papers women were urged to attend the 
screening. 
The smears were made by experienced smear-takers m a mobile van 
which was driven to the municipalities where the women were l iv ing. 
Before the smear was made several questions were asked about the 
number of pregnancies, menstrual history and the method of contra-
ception. 
All smears were processed at the Cytopathology Laboratory of the 
Department of Pathology, University of Nijmegen and screened by 
experienced cytotechnologists. Cytological findings were recorded in 
terms of the Papanicolaou classification, to which a description of 
cytological findings in the smear was added. Each descriptive diagno-
sis comprised 4 terms indicating- 1. the cellular composition of the 
smear 2. the presence or character of inflammatory changes 3. the 
expected histopathologic change m the squamous or squamous meta-
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plastic cervical mucosa 4. changes in columnar cells from the endocer-
vical mucosa or an abnormality related to the endometrium. In case of 
an abnormal cervical cytological finding the general practitioner was 
contacted who was responsible for the recommended follow up. 
When the cytological diagnosis was consistent with a severe dysplasia, 
a carcinoma in situ or an invasive cancer, the general practitioner 
was asked to refer the woman to a gynecologist. In case of a cytolo-
gical diagnosis consistent with a slight or a moderate dysplasia, the 
general practitioner was requested to make a repeat smear after six 
or three months respectively. The laboratory checked whether the 
advice was followed and if not, the general practitioner was contacted 
and reminded of the recommended follow up. All cytological and his-
tological diagnoses from women participating in the screening pro-
gramme were collected from pathology laboratories serving the area 
and linked with the cytological diagnosis of the population screening 
smear. 
Diagnosis and treatment of cervical abnormalities is not yet uniform in 
The Netherlands. For confirmation of cytological diagnoses, random 
biopsies, biopsies directed by colposcopy, curett ings, cone biopsies 
and sometimes hysterectomies are performed. Recently random biopsies 
are increasingly replaced by biopsies directed by colposcopy. 
Results 
Attendance rate 
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Overall attendance rates were 74°o, 670o and 63o at f i r s t , second and 
third screening respectively. 
In the course of the nine year screening programme attendance rates 
declined in all age groups but the youngest (35 through 37 years). 
These women were invited in second and th i rd screening period for 
the f i rst time. 
Attendances rates were lower with increasing age and differed sub-
stantially in the 62 communities In urban communities attendance 
rates were considerably lower compared to rural areas Unmarried, 
divorced, as well as widowed women were less likely to participate. 
Cytological results 
In Table 5 the cytological results of f i rs t , second and th i rd screening 
are summarized As expected the number of severe epithelial abnor-
malities was highest at f i rst screening. At f i rs t screening quite a 
number of women had a cytological smear taken for the f i rs t time in 
their life (570o). The percentage of severe epithelial abnormalities at 
second and th i rd screening was almost the same Compared to the 
f i rst screening period the number of cervical smears suspicious of 
(micro)invasive squamous cell cancer declined considerable at succes-
sive screenings. At f i rs t screening the number of severe epithelial 
abnormalities was highest m women aged 53 through 55 years. At sec-
ond and th i rd screening the number of severe epithelial abnormalities 
was equally distributed over the different 3-year age groups. How-
ever this reduction in the number of severe epithelial abnormalities 
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was not seen in the age group of women 35 through 37 years who in 
each three year screening period were invited for the f i rst time 
The number of smears with a cytological diagnosis consistent with 
moderate dysplasia was increased after the f i rst screening period. 
However this is partly due to changes in diagnostic procedures in the 
laboratory 
Table 5 
Distribution of epithelial abnormalities in cervical smears from 
participating in the screening programme 
Cytological 
diagnosis 
consistent with 
No abnormalities 
Slight atypia 
Slight dyslasia 
Moderate 
Dysplasia 
Severe dysplasia 
and 
Carcinoma in situ 
(Micro)invasive 
cancer 
Total 
Screening pe 
First Second 
Ν N 
« · 
62 244 
99 S". 
118 
о m 
164 
0 26-. 
25 
0 04% 
62 551 
100% 
57 360 
99 5% 
181 
0 32% 
126 
0 22% 
5 
0 009% 
57 672 
100% 
nod 
Third 
N 
54 360 
99 5% 
150 
0 27% 
125 
0 23% 
2 
0 004% 
54 637 
100% 
women 
Rank of smear 
(3-year interval) 
1 2 3 
N N N 
% % X 
44 384 
99 0% 
98 
0 22% 
153 
0 34% 
22 
0 05% 
44 657 
100% 
51 669 
99 6% 
144 
0 28% 
84 
0 16% 
2 
0 004% 
51 899 
100% 
22 067 
99 7% 
38 
0 17% 
31 
0 14% 
-
22 136 
100% 
In the same table the cytological results of f i r s t , second and th i rd 
smears are compared The figures illustrate clearly the effect of pre­
vious screenings In f i rs t cervical smears severe epithelial abnormali­
ties were discovered m 3 9 per thousand smears, in second smears m 
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1.7 per thousand smears and in th i rd smears in 1.4 per thousand 
smears. This means a reduction m the number of severe epithelial 
abnormalities by more than 100oo diagnosed in second and th i rd smears 
compared to the number found m f i rst smears. 
In 51.899 women who were screened twice in only two women the sec-
ond smear was suspicious for (micro)invasive cancer In women who 
were screened three times not one smear was found to be suspicious 
for (micro)invasive cancer at th i rd screening. 
Changes m the number of smears consistent with moderate dysplasia 
are difficult to interpret since the diagnostic laboratory procedure 
was changed during the years of the screening programme towards a 
higher sensitivity for slight to moderate epithelial changes However 
m women who were screened three times a tendency to a lower inci-
dence of moderate dysplasia was seen m comparison to those women 
who were screened twice. 
Tissue diagnosis and predictive value. 
During the screening programme 447 women were referred to a gyne-
cologist because of a cytological diagnosis consistent with a severe 
epithelial abnormality. 
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Follow up diagnoses in these women are summarized in Table 6. 
Table 6 
Follow up diagnosis after cyt 
dysplasia, carcinoma in situ 
Follow up diagnosis 
No abnormalities 
Slight atypia or 
Slight to moderate dysp 
Severe dysplasia 
Carcinoma in situ 
(Micro)invasive cancer 
Repeat smear only 
No follow up available 
Total 
Predictive value 
Cytological diagnosis i 
Lasia 
ological diagnosis 
and (micro)invasive 
Screening 
First 
1-8-1976/ 
31-7-1979 
17 
118 
34 
17 
3 
189 
82-. 
severe dysplasia 
consistent with severe 
cancer 
period 
Second 
1-8-1979/ 
31-7-1982 
27 
85 
4 
15 
-
131 
68Ï 
Third 
1-8-1982/ 
31-7-1985 
29 
63 
3 
26 
6 
127 
55* 
Total 
73 
16% 
266 
60% 
41 
9% 
58 
13% 
9 
2% 
447 
70% 
Of 9 (20o) women fol low up diagnosis was not yet avai lable at the con-
clusion of th is s t u d y . 
In 58 (130o) women fol low up was limited to a repeat smear. In these 
smears no abnormali t ies were found and t issue diagnosis was not con-
s idered necessary These women were f u r t h e r fol lowed by repeat 
cyto logical smears In 73 (160o) women the t issue diagnosis showed 
none or on ly s l igh t epi thel ia l abnormal i t ies. In 307 (69*0) women the 
severe abnormal i ty was conf i rmed at histological d iagnos is . The p r e -
d i c t i ve values f o r the d i f f e ren t screening per iods f o r severe ep i the l i -
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al abnormal i t ies, severe dysp las ia , carcinoma in s i tu and 
(micro) invas ive cancer were 820o at f i r s t sc reen ing , 680o at second 
screening and 54o at t h i r d screening Th is decl ine in p red i c t i ve v a l -
ue is a consequence of the decreasing number of severe epi thel ia l 
abnormalit ies m a screened populat ion ( 5 ) . 
When a cytological diagnosis of a smear was consistent w i th moderate 
dysplas ia, a repeat smear a f ter th ree months was advised When the 
cytological diagnosis of such a repeat smear was comparable w i th the 
f i r s t diagnosis o r suggested a more severe lesion the women were 
re fe r red to a gyneco log is t . In Table 7 ' f i na l ' diagnoses of women w i th 
smears consistent w i th moderate dysplasia are summarized. 
Table 7 
"Final" diagnosis after 
dysplasia 
Follow up diagnosis 
No abnormalities 
Slight atypia or 
Slight to moderate 
dysplasia 
Severe dysplasia 
Carcinoma in situ 
(Micro)invasive cancer 
Adenocarcinoma 
Repeat smear only 
No follow up available 
Total 
% of women with 
severe abnormality at 
histological diagnosis 
cytological 
Screening 
First 
1-8-1976/ 
31-7-1979 
28 
30 
2 
56 
2 
118 
2 % 
diagnosis consistent with moderate 
period 
Second 
1-8-1979/ 
31-7-1982 
20 
40 
3 
110 
8 
181 
25% 
Third 
1-8-1982/ 
31-7-1985 
29 
14 
-
1 
90 
16 
150 
10% 
Total 
77 
17% 
84 
19% 
5 
1% 
1 
0.2% 
256 
57% 
26 
6% 
449 
22% 
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During the screening programme in 449 women a cytological diagnosis 
consistent with moderate dysplasia was made. 
Of 26 cases (60o) follow up is not (yet) available. In 167 women (37%) 
repeat cytological diagnosis was follcwed by histological examination of 
the cervix In 90 women (21%) of the total group a severe epithelial 
abnormality was diagnosed 
If we calculate the percentage of severe abnormalities m the group 
women with a cytological diagnosis consistent with moderate dysplasia, 
the conclusion can be drawn that the percentage of severe epithelial 
abnormalities is reduced from 28% during the f i rs t screening to 25% 
during the second screening period and to 10% during the th i rd 
screening period. Finally m 5 women after an initial cytological diag-
nosis "moderate dysplasia" at follow up invasive cancer was diag-
nosed The smears of these five women were reviewed, three smears 
were not correctly screened Review diagnosis was consistent with 
severe dysplasia (screening er ror ) . The review of the other smears 
did not alter the cytological diagnosis consistent with moderate dys-
plasia It can be concluded that the sample was inadequate (sample 
er ror ) . 
Of 46 invasive cancers (41 after a cytological diagnosis consistent 
with severe dysplasia and 5 after a cytological diagnosis consistent 
with moderate dysplasia) 28 were found to be microinvasive (IA, with 
an invasion depth less than 5 mm), 7 cancers were found m clinical 
stage IB, 4 were found m stage MA, 3 cancers were m stage MB and 
1 cancer was m stage I I I . In three women clinical stages were 
unknown 
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Treatment 
For women who had a cytological diagnosis consistent with severe 
dysplasia, carcinoma m situ and (micro)invasive cancer (N = 353) 
during the f i rs t seven years of the population screening programme, 
we registered what final treatment was given. Six women were 
already known with cervical abnormalities before they participated in 
the population screening programme and of six women no follow up 
results could be traced. In Table 8 final treatment according to tissue 
diagnosis is given for the remaining 341 women 
Table 8 
Therapy according 
Histological 
diagnosis 
No or only slight 
abnormalities 
Moderate dysplasia 
Severe dysplasia 
Carcinoma in situ 
(Micro)invasive 
cancer 
No histological 
diagnosis 
to previous 
Therapy 
None 
19 
7 
10 
-
37 
histological 
Ablatio 
biopsies 
4 
9 
-
-
Coni-
sation 
7 
2 
14 
1 
3 
diagnosis 
Hyster­
ectomy 
10 
14 
160 
β 
15 
Radical 
hyster­
ectomy 
-
1 
7 
-
Radio­
therapy 
1 
3 
9 
-
Total 
41 
23 
197 
25 
55 
T o t a l 73 13 27 207 β 13 341 
21·". 4% 8% 6 1 % 2% 4% 1 0 0 % 
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The therapy which was applied most frequently was simple hysterecto-
my (610o). In three women conisation was performed without previous 
histological diagnosis, because the conisation was performed for diag-
nostic reasons. The same explanations can be given for conisations 
after none or only slightly abnormalities of the cervix; the conisation 
was part of the diagnostic procedure. 
In case of the 15 women, who received hysterectomy without previous 
histological diagnosis, it is likely that there was done histological 
examination of the cervix but the results could not be traced. Some-
times a serious discrepancy between cytological diagnosis and histolo-
gical diagnosis was the reason for hysterectomy. Radiotherapy is the 
therapy of choice in case of invasive squamous cell cancer, clinical 
stage I IB, III or IV. In some other cases radiotherapy was chosen 
because the macroscopic view at laparotomy and the general state of 
health which was too bad to perform hysterectomy. Since it was not 
possible to evaluate other factors which could have influenced therapy 
choice, the interpretation of the figures is di f f icul t . The ablatio is a 
therapy, which is yet only performed in one hospital in the region, 
but which is likely to become the treatment of choice in future for 
histologically confirmed severe dysplasia and carcinoma in si tu. 
There is a growing awareness among gynecologists that conisations 
formerly considered to be the treatment of choice for severe epithelial 
abnormalities might be considered as overtreatment. A protocol for a 
more conservative surgical approach for these intraepithelial lesions is 
presently under consideration. 
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Discussion 
When analysing the number of severe epithelial abnormalities diag-
nosed in women who participated twice or three times in the screening 
programme, it becomes evident that screening with a 3-year interval 
is effective in reducing the prevalence of severe epithelial lesions. 
In Table 9 the number of severe epithelial abnormalities, confirmed by 
histological diagnosis, per thousand cytologically screened women is 
summarized At f i rs t screening severe abnormalities were diagnosed in 
3.0 per thousand. At second screening in 2.3 per thousand and at 
th i rd screening only in 1 5 per thousand cytologically screened 
women. 
Table 9 
Histological diagnosis. Number of histological diagnoses 
dysplasia, carcinoma in situ and (micro)invasive cancer 
cytologically screened women 
Screening 
period 
First 
Second 
Third 
Tissue diagnosis Number of 
screened woman 
Severe dysplasia 
Carcinoma in situ 
(Micro)invasive cancer 
185 62.551 
133 57.672 
80 54 637 
with severe 
jer thousand 
Per 
thousand 
3.0 
2.3 
1.5 
Rank of smear 
(3-year interval) 
First 
Second 
Third 
169 44.657 
54 51 899 
15 22.136 
3.8 
1.0 
0.7 
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When comparing the number of severe abnormalities found in women 
who were screened for the f i rst time with the number found m women 
who were screened twice or three times with an interval of three 
years, the reduction was even greater; 3.8 per thousand in f i rst 
smears, 1.0 per thousand m second smears and only 0.7 per thousand 
in th i rd smears. On the basis of these findings we may conclude a 
screening policy with an interval of three years to be a safe proce-
dure. Whether this interval is the most efficient cannot be conclud-
ed. We have the impression that an interval of four to six years may 
lead to comparable results. 
A small number of women (N = 4435) was screened twice with an 
interval of six years (participation in f i rs t and thi rd screening 
round). The number of severe epithelial abnormalities in second 
smears m these women was equal to that in women who were screened 
twice with an interval of three years. However the number of women 
screened with an interval of 6 years is still too small for definite con-
clusions. 
To assess the effectiveness of a cervical screening programme, it is 
not sufficient to register disease processes m the population who 
joined the programme The number of women with a previous negative 
smear and an abnormality diagnosed some time later outside the pro-
gramme should be known as well. Furthermore it should be checked 
whether the r ight population was screened. To address the f i rst 
problem we checked for all women registered m our cancer registry if 
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they participated in the population programme and if so we linked the 
cytological result with the information registered in the cancer regis-
t r y . In two successive screening periods of three years each 120.223 
smears were made. Within 48 months after a negative cytological smear 
45 women were entered in the cancer registry with a histological diag-
nosis of a severe epithelial abnormality of the uterine cervix. The 
number of true positives in that same period was 235 thus the sensi-
t iv i ty could be assessed at 840o. Of course this is an estimate which 
bears some inaccuracies but it is a good indicator of the quality of 
the test (6). In order to verify whether we screened the right popu-
lation we monitored the incidence of invasive cervical cancer in the 
entire population 
In the period prior to the population screening programme (1970-1976) 
the yearly incidence of invasive cervical cancer was 18.6 per 100.000 
in women aged 35 through 54 years. During the f i rs t screening period 
21.5 per 100.000 women, m the second screening period 9.0 per 
100 000 women and 3 3 per 100.000 women during the th i rd screening 
period (7). Thus some years after the introduction of population 
screening the incidence of invasive cervical cancer dropped considera-
bly This decline is not only a consequence of the screening pro-
gramme since also outside the screening programme a considerable 
number of smears was made for preventive reasons by general prac-
titioners and it is impossible to separate the effect of the regular 
screening programme and the latter activity of general practitioners. 
During the f i rst screening period (1976-1979) 860o of women aged 35 
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through 54 years had at least one smear made by a general practi-
tioner or gynecologist or within the screening programme. 
During the second screening period (1979-1982) 80% of the female 
population had at least one smear made in or outside the organized 
programme (7). Summarizing, the conclusion is justified that the 
Dutch screening programme proved to be effective in reducing mor-
bidity due to cervical cancer and could be compared with the succes-
ful programmes which were carried out in the Scandinavian countries 
(8-11). On the basis of the preliminary results of the three pilot 
screening projets the Dutch government decided that cytological 
screening for cervical cancer should be implemented in the general 
practice. An accurate registration system, proper follow up of abnor-
mal smears and a good quality control of cytological smears and labo-
ratory procedures are conditions for an effective screening pro-
gramme. The failure of the cervical cancer screening programme in 
the United Kingdom was attributed to several of the above mentioned 
factors (12-14). Several questions remain unanswered, such as the 
optimal screening interval and should women below 35 years of age be 
screened periodically. A large study coordinated by the International 
Agency for Research on Cancer, and based on ten screening pro-
grammes in different parts of the developed world revealed that the 
risk of invasive cancer during the f i rst 2 years after a negative 
smear was low compared to the risk prior to screening. The protec-
tion decreased gradually but some protection was seen up to ten 
years after the cytological smear (15). Invasive cancer below the age 
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of 35 is rare and mortality from cervical cancer below the age of 35 
year is extremely low. Since the objective of screening for cervical 
cancer is to prevent invasive disease, extending the programme to 
younger ages does not seem necessary at this moment. The number 
of invasive cancers below the age of 35 years should be monitored 
and the screening policy should be reviewed regularly for its val idi-
ty . 
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CHAPTER ЧА 
THE EFFECTIVENESS OF CERVICAL SCREENING. A 
POPULATION-BASED CASE-CONTROL STUDY* 
Yolanda van der Graaf MD, Gerhard A Zie lhuis MSc, PhD, Petronella 
GM Peer MSc, Peter G Vooijs MD, PhD 
Summary 
T h e cerv ica l smear h i s t o r y of 36 women w i t h invasive cerv ica l cancer 
was compared to t h a t of 120 age-matched c o n t r o l s , d r a w n f r o m local 
r e g i s t r a r s off ices 
Of t h e cases 47o were screened at lf»ast once, whi le of t h e contro ls 
t h i s f i g u r e was 680o The relat ive r i s k of g e t t i n g invas ive cerv ica l 
cancer f o r women e v e r screened compared t o women who were never 
screened was 0 32 T h e most important confounder was age at f i r s t 
i n t e r c o u r s e C o n t r a r y to o t h e r studies however, we not iced t h a t 
women who were y o u n g e r when having f i r s t i n t e r c o u r s e were screened 
more o f t e n . A f t e r c o r r e c t i n g the re lat ive r i s k screened v e r s u s 
unscreened f o r age at f i r s t in tercourse t h e re lat ive r i s k became 0 22. 
When t h e length of t h e i n t e r v a l since t h e last smear was c o n s i d e r e d , 
th e re lat ive r isk was 0 18 when the smear was made between 2 and 5 
years ago and 0.30 when th is smear was made more t h a n 5 years ago. 
*J Chron Dis In Press 
page 52 Screening for cervical cancer 
This study supports the assumption that screening is effective in the 
prevention of invasive cancer of the uterine cervix. Even a screening 
interval of more then 5 years gives a considerable protection. 
Introduction 
The evidence suggesting the effectiveness of cervical screening in 
reducing the occurence of cervical cancer is impressive (1-7). Most 
studies however are based on comparisons of incidence and mortality 
rates between populations with different screening intensity. Compari-
sons were made either between countries or regions for a given time 
period, or were done within a particular population group in different 
time periods. Since in these studies serious bias may have occurred, 
a causal relationship between cervical screening and a reduced risk 
for invasive cervical cancer has been questioned for a long time. 
Basically the problem can be defined as the lack of a properly 
designed randomized controlled t r ia l . Such a tr ial has never been 
performed and never will be, because cervical screening has already 
been widely accepted by the public and by the health authorities as a 
useful practice. Once a form of screening has become wide spread, 
the case-control study can be used to monitor the effectiveness of the 
screening programme (8). Clarke and Anderson (9) and later La 
Vecchia et al (10) and Aristizabal et al (11) performed case-control 
studies in which women with invasive cervical cancer were compared 
to healthy controls in respect to their screening history. These stud-
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íes were critisized on methodological grounds (12-14) In two of the 
above mentioned studies, women with microinvasive cancer were 
included m the case-group (9 11). In one study women with carcino-
ma m situ and microinvasive cancer W3re included in the case-group 
(10) Carcinoma in situ and microinvasive cancer are symptomless and 
thefefore only detectable by active, early recognition procedures such 
as screening 
Consequently, a screened population will have a higher rate of any 
disease manifestation discovered during the lead-time interval, the 
period between the time that the disease is detected by screening and 
the time that diagnosis would have occured in the absence of screen-
ing Thus, if a person is considered to be a case on the basis of a 
characteristic of disease that comes to attention during the lead-time 
interval, there will be an excess of screen-detected cases, and a ben-
eficial effect of screening could be obscured (12) We performed a 
case-control study which largely overcomes this deficiencies by 
excluding the preclinical cervical cancers. Only the more advanced 
stages of cervical cancer were included. In this study too, the 
objective was to analyse failure to participate m a screening pro-
gramme as a potential risk factor for invasive cancer 
Population and methods 
In the region of the city of Nijmegen, population screening for cervi-
cal cancer started in 1976. Every three years, all women m the age 
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group 35-55 years are invited for a cervical smear Apart from the 
screening programme an increasing number of smears is being made 
by general practitioners and gynecologists All data were stored on 
tape The results of the smears made by general practitioners and 
gynecologists were linked with the files of the population screening 
programme Thus, we were able to check the complete screening his-
tory for all women born between 1922-1943 (the bir th cohorts eligible 
for population screening) 
Data on the incidence of invasive cervical cancer in the region of 
Nijmegen are available from the local cancer registry which has been 
kept since 1970 From the files of this cancer registry we chose 
women eligible for our study Cases were defined as women having 
invasive cervical cancer, stages IB through IV, diagnosed between 
1-8-1979 and 1-8-1985 and who were younger than 70 years of age at 
the time of diagnosis Of the 67 eligible cases, 64 were diagnosed 
clinically and 3 were detected in the population screening programme 
For each case 6 age-matched controls (same year of birth) were 
drawn from the local registrar's office Because the size of the study 
was restricted by the number of available cases we increased the 
power of the study by invit ing 6 controls per case The controls 
were to be currently married or to have been married in order to be 
at risk for cervical cancer Women who underwent a hysterectomy for 
non malignant reasons were excluded as controls Cases were 
informed by the gynecologist about the study Controls were con-
tacted by mail If women consented to participate they were asked to 
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f i l l in a questionnaire which was checked and completed by a trained 
interviewer visit ing the woman at her home address. All cases and 
controls were interviewed within a period of six months. 
The questionnaire was designed to obtain detailed information about 
screening history and potential confounders. 
Information was obtained on the number of cervical smears made, the 
length of the interval between the smear and the date of diagnosis of 
the case, the reason for taking the smear and the profession of the 
person who made the smear. For cases as well as for controls only 
the preventive smears, which were made at least one year before the 
case was diagnosed were taken into consideration. This was done to 
exclude smears which were actually taken as part of the diagnostic 
process. A preventive smear was defined as a smear taken for rea-
sons other than non cyclic bleeding, vaginal discharge or pelvic pain. 
As potential confounders were considered number of children, age 
when f i rst child was born, use and duration of oral contraceptives, 
school education, smoking history, age at f i rst intercourse and num-
ber of partners when the woman was under 20 year of age and 
between 20 and 30 year of age. Using the conditional logistic regres-
sion model for matched series, the odds ratio associated with screen-
ing was estimated by maximum likelihood (15) This measure of effect 
can be considered as an estimate for the relative r isk. 950o confi-
dence intervals were computed. 
Results 
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Of the 67 eligible cases only 37 could be interviewed. 16 women died, 
4 were too ill to be interviewed, 4 could not be traced and 6 women 
refused to participate. For one case no controls were obtained. Thus 
the analysis is based on a case series of 36 women. Of these women 
20 were above the age of 50 when the cancer was diagnosed and 16 
below the age of 50. 216 controls were invited to participate m the 
study. Of these 120 agreed to participate. 
Information about the screening history showed that of the cases 47% 
had had at least one cervical smear compared with бВ" of the controls 
(Table 10). 
Table 10: 
Frequency of 
Cases 
Controls 
Total number 
cervical screening 
Screened 
N 
17 (471) 
81 (681) 
98 
among cases and controls 
Never screened 
N 
19 (531) 
39 (321) 
58 
Total 
N 
36 (1001) 
120 (1001) 
156 
In Table 11 the distribution of the 36 case-control combinations is 
given. The matching ratio diverged from one-to-one to onç-to-five 
case-control combinations. Calculation of the odds ratio taking the 
matching into account, as described by Breslow & Day for the 
complex situation of different matching ratio's, leads to an estimate of 
0.32 (950o confidence interval 0.12-0.80) (15). 
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Table 11. 
Distribution 
Case 
ratio 
1 . 1 
1 . 2 
1 3 
1 · 4 
1 5 
of 
control 
Odds ratio = 0. 
36 
32 
case control 
Screening 
status of 
+ 
+ 
+ 
+ 
+ 
case 
combinat ions, 
Number of 
0 
1 
4 
1 
1 
1 
1 
2 
1 
2 
(95% confidence interval 
screened vs 
contro 
2 
2 
2 
1 
2 
0 12 -
s ser 
3 
4 
1 
1 
2 
0 87] 
unscreened 
eened 
4 5 
4 
1 
2 
1 
Total 
1 
1 
1 
2 
7 
β 
6 
7 
2 
1 
¡ 
Other risk factors 
Considered as potential confounders for the relation between cervical 
screening and the risk of invasive cervical cancer were the following 
risk factors: age at f i rs t intercourse (<20 and > 20), numbers of 
partners when the woman was under 20 years of age (<2 and > 2) , 
and when between 20 and 30 years of age (<2 and > 2) , use of oral 
contraceptives (yes or no), smoking (yes or no) and level of educa-
tion (primary school or primary school and upwards). 
In order to be able to correct for confounding we performed a 
stepwise-forward logistic regression analysis Risk for disease was the 
dependent variable, screening history and potential confounders were 
independent variables. 
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As we were interested in the relation between disease and screening 
history, screening history was always entered in the model The 
odds ratio for screened versus unscreened was influenced the most 
when age at f i rst intercourse was entered in the model. The adjusted 
odds ratio for screened versus unscreened was estimated at 0 22 (95% 
confidence interval 0 07-0 69) After controlling for age at f i rs t 
intercourse no other variables influenced the odds ratio for screened 
versus unscreened. After matching for age and marital status, con-
trol l ing for age at f i rs t intercourse appeared to be sufficient to obtain 
an estimated relative risk not biased by other confounders. 
When also the length of the interval since last smear was taken into 
account the relative risk for women whose smear was made between 2 
and 5 years ago compared with women who were never screened was 
0.18 (950o confidence interval 0.05-0.62). For women whose smear was 
made more than 5 years ago the relative risk was 0.30 (95% confidence 
interval 0 09-1 02). In Table 12a and 12b all relevant findings are 
summarized. 
Table 12a: 
Relative risk of getting invasive cervical cancer 
compared to women who were never screened 
Unadjusted 
Relative risk 0.32 
95\ confidence Interval 0.12-0.80 
for women ever screened 
Adjusted for age 
at first intercourse 
0.22 
0.07-0.69 
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Table 12b: 
Relative risk of getting 
of the screening interval 
at first intercourse 
Relative risk 
95·". confidence interval 
invasive cervical cancer according to the lenght 
, relative to never screened. Adjusted for age 
Last smear 
2-5 years ago 
0.32 
0.12-0.80 
Last smear 
>5 years ago 
0.22 
0.07-0.69 
Discussion 
Our study confirms the assumption that cervical screening reduces 
the incidence of cervical cancer. Three potential problems associated 
with case-control studies have to be discussed: selection bias, infor-
mation bias and confounding. 
Selection bias 
In our study cases were selected from the files of the regional cancer 
registry. It is reasonable to assume that all women with cervical can-
cer in the Nijmegen region in the given time period were registered, 
but not all cases could be included in the study. From those who 
were not included 16 had died and 4 were too ill to be interviewed, 
which means that the most severe cases were not included in the 
study group. It is very unlikely that the women with more advanced 
tumors were screened more often. 4 cases could not be traced, 
because they moved away. 2 women refused to participate because of 
the sensitive nature of the questions and 4 refused because they felt 
psychological not strong enough to talk about things that had to do 
with their disease. There is no reason to suppose that those women 
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were screened more often. To study possible selective non response 
we could make use of the files of the population screening programme 
and the files with results of all smears made by general practitioners 
and gynecologists. These files were complete for all women born 
between 1922-1943 (550o of the invited women). From the non included 
cases 380o was screened at least once compared to 550o of the included 
cases. 
Also for the other birth cohorts it is likely that if any selective non 
participation exists, these non participants were screened less than 
the cases included in the study. Correction for this possible bias 
could only lead to a relative risk more away from unity. 
Only бСУо of invited controls agreed to participate in this study. As 
we did for the cases we compared the screening history of the non 
response group with that of women who did respond in the subgroup 
of women born between 1922 and 1943. Of the women in the response 
group 9Cfo was screened at least once, whereas in the non response 
group this percentage was 850Ó. Even though some selection bias seems 
to exist this difference is thought to be too small to be able to 
account for the relative risk of 0.22. 
Information bias 
Women who were interviewed had to go back in their memory a long 
time. For this reason information about former smears may not have 
been exact. For women born between 1922 and 1943 the screening his-
tory could be checked using the files of the population screening pro-
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gramme. Also for cervical smears made outside the programme a com-
puterized file is available for women m this age group. Accuracy 
proved to be nearly 100% There was some discrepancy between 
mtreview and the information on tape in the number of screens and 
the correct date of the smear. There was no discrepancy about the 
question if a women was screened or not. 
Confounding 
Known risk factors for cervical cancer have been shown to be 
inversely related to the attendance for screening. Sexual habits are 
known to be related to cervical cancer. Early start of sexual activity 
and sexual activity with multiple partners have appeared as risk fac-
tors m almost every epidemiologic study (16-20). Also in our study 
cases were younger when having f i rst intercourse (Table 13a). 
Table 13a. 
Age at f i r s t 
Cases 
Controls 
intercourse 
Age 
<20 
42*. 
30". 
at 
among 
f i r s t 
cases and controls 
intercourse 
20-25 
47*. 
38% 
>2S 
11% 
33% 
T o t a l 
N= 36 
N=120 
T o t a l N=156 
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It was an unexpected finding that women having f i rs t intercourse at a 
younger age were screened more often (Table 13b) 
Table 13b 
Age at first intercourse according to screen ing history 
Age at first intercourse 
Screened 
Unscreened 
Total 
<20 20-25 
4 Π 40% 
19% 40% 
>25 
19% 
41% 
Total 
N= 98 
N* 58 
N»156 
Possibly, these days Dutch women who have intercourse at a young 
age are aware of a higher risk for cervical cancer which results in a 
better participation in screening programmes. In our study 17% of 
the cases had more than one partner, whereas for the controls this 
percentage was 70o The number of partners proved to be strongly 
related to the :>ge at f i rs t intercourse After controlling for this lat­
ter variable the number of partners had no separate effect on the 
relative risk screened versus unscreened Questions about age at 
f i rs t marriage and age at f i rst childbirth were asked, to replace 
questions about sexual behaviour if necessary All women however 
gave answers to questions about sexual behaviour When checked for 
consistency with age at f i rst marriage and age at f i rs t childbirth 
these answers proved to be reliable 
Use of oral contraceptives could not be confirmed as a risk factor in 
our study Screening history was strongly related to the use of oral 
contraceptives but oral contraceptive use did not differ significantly 
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between cases and controls. Also when the duration of oral contracep-
tive use was taken into account there was no difference between cases 
and controls. This is in contrast with the study of Vessey et al but 
is in accordance with studies of Boyce, Wright, Worth, Thomas and 
Peritz (21-25). 
Winkelstein was the one who f i rst put forward the hypothesis that 
smoking was a risk factor for cancer of the uterine cervix (26). 
Several studies showed a relation between cigarette smoking and cer-
vical cancer (27-35). Many variables related both to cigarette smok-
ing and to known risk factors for cervical cancer are sources of con-
founding. Inadequate control for these variables may cause an 
overestimation of the effect of smoking (36). In our study smoking 
was highly related with age at f i rst intercourse. After adjusting the 
relative risk for this confounder, smoking had'no separate effect on 
the relative risk anymore. 
From the results of our study it can be concluded that cervical 
screening offers a strong protection for the development of cervical 
cancer. The relative risk for screened compared with unscreened 
women is 0.22. If the length of the time-interval since last screening 
is taken into account, a cervical smear made between 2 and 5 years 
ago leads to a relative risk of 0.18 which is a f ive fold decreased 
risk. But even an interval of more than five years seems to offer a 
considerable protection. The estimated relative risk for women who 
were screened more than 5 years ago compared with unscreened 
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women was 0.30. Age at f i rst intercourse proved to be the major 
risk factor. However in our study women at greater risk appear to 
have more often cervical smears made for preventive reasons. 
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CHAPTER IB 
EFFECT OF POPULATION SCREENING FOR CANCER OF 
THE UTERINE CERVIX IN NIJMEGEN. THE 
NETHERLANDS* 
Yolanda van der Graaf MD, Paul JJM Kl inkhamer MD, Peter G Vooijs 
MD, PhD 
Abs t rac t 
Since the i n t roduc t i on of a populat ion screening programme fo r c e r v i -
cal cancer in 1976, more than 850Ó of the female populat ion between 
the ages of 35 and 54 years in the region of the c i t y of Ni jmegen, 
The Nether lands has been screened. A t f i r s t sc reen ing , severe 
epi thel ia l abnormal i t ies were diagnosed in 4 .4 per 1000 women, at sec-
ond sc reen ing , in 1.5 per 1000; and at t h i r d sc reen ing , in 1.0 per 
1000. The populat ion screening programme led to a marked increase 
in t h e detected number of carcinomata in s i t u . The number of cases 
of squamous cell cancer diagnosed in the f i r s t screening per iod d id 
not increase. Once the populat ion was screened, the detect ion rate of 
invas ive squamous cell cancer in the g roup of women ages 35 t h rough 
54 decreased f rom 18.6 per 10 ' d u r i n g the per iod p r i o r to the screen-
ing t o 9.0 per 105 a f te r the f i r s t screening and 3.3 per 10* a f te r the 
second sc reen ing . For the women above age 54, the incidence of 
*Prevent /Ve Medicine 1986; 15: 682-690 
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invasive cancer was reduced by 580o after the second screening 
The number of invasive cancers diagnosed m women under age 35 
remained relatively small in spite of the large number of cases of car-
cinoma m situ 
Introduction 
The efficacy of cervical cancer screening has never been tested by 
randomized t r ia l , and it is unlikely that such a tr ial can ever be per-
formed m the future Results from observational studies, however, 
offer more and more evidence that the implementation of the Pap 
smear can reduce morbidity and mortality from cervical cancer (1-6) 
In The Netherlands, where population screening for cervical cancer 
began in the mid-1970s, it is still too early to see changes m mortali-
ty figures as a result of the screening Mortality is declining since 
1962, long before cervical smears were used to detect preinvasive 
lesions (7) The mortality figures are largely a result of invasive 
tumors diagnosed prior to the start of the population screening pro-
gramme (Figure 8) 
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Figure 8: Standardized morta l i ty rat ios and 95o conf idence i n t e r v a l s 
f o r c e r v i c a l cancer in The N e t h e r l a n d s , 1936-1983 
Population s c r e e n i n g programmes p r i m a r i l y use t h e cerv ical smear t o 
detect p r e i n v a s i v e p r e c u r s o r lesions. T h e r e f o r e , t h e effect iveness of 
a screening programme can also be evaluated b y d e t e r m i n i n g changes 
m t h e incidence rate of invasive cancer. A s h i f t m t h e d i s t r i b u t i o n 
t o w a r d a more f a v o u r a b l e stage of i n v a s i v e cancers in a screened 
g r o u p is of l imited v a l u e , however, since such a s h i f t can occur even 
when t h e outcome is not i m p r o v e d , due to t h e lead time and l e n g t h 
t ime b ias. (Lead t ime is t h e time p e r i o d b y w h i c h t h e diagnosis of 
cancer is moved back in t ime as a r e s u l t of e a r l y d e t e c t i o n ; L e n g h t 
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time bias is the result of the fact that slow-growing lesions are more 
likely among screen detected cases.) 
Methods 
Since august 1976 a population-based screening programme for cervi-
cal cancer has been in progress in the region of the city of Nijmegen, 
The Netherlands. This programme is part of a pilot study initiated 
by the Dutch government m the cities of Nijmegen, Rotterdam and 
Utrecht to determine the organizational implications and the possible 
impact of a nationwide screening programme for cervical cancer. The 
Nijmegen region comprises 735 000 inhabitants. All women ages 35 
through 54 (approximately 88.000) were invited to participate after 
their names were obtained from city and local registries 
Smears were taken with an interval of 3 years Women were invited to 
attend a mobile clinic m their residential areas. 
A single cervical smear was taken with a slightly modified, pointed 
wooden Ayre spatula. The smears were taken by trained women, were 
processed at the Cytopathology Laboratory of the Department of 
Pathology, University of Nijmegen, and were screened by experienced 
cytotechnologists 
In the case of abnormal cervical cytological findings the general prac-
tit ioner was contacted. He or she was requested to inform the woman 
and was responsible for the recommended follow up. When the cytolo-
gical diagnosis was consistent with a severe dysplasia, a carcinoma in 
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situ or an invasive carcinoma, then a referral to a gynecologist was 
recommended. In the case of a cytological diagnosis consistent with a 
slight or moderate dysplasia, the general practitioner was requested 
to take a repeat smear after either 6 or 3 months, respectively. The 
laboratory checked whether the advice had been followed, and if not, 
the general practitioner was contacted and reminded of the recom­
mended follow up. 
Apart from the population screening programme, smears were obtained 
from general practitioners' and gynecologists' practices These 
smears were made on the initiative of the women themselves. Unfor­
tunately, it is not known whether the smears were made for preven­
tive reasons or for gynecologic complaints. 
The results of these smears taken from women between ages 35 and 
54, made since August 1, 1975 (ι e one year prior to the start of 
the population screening programme) were linked with the results of 
the population screening programme. In this article screening results 
from the period prior to the screening programme (August 1, 1975 -
July 3 1 , 1976) and those from two screening rounds (August 1, 1976 
- July 31, 1982) are presented. 
Cytological findings were recorded in terms of the Papanicolaou classi­
fication, to which a description of cytological findings in the smear 
was added. Each descriptive diagnosis comprised four terms indicat­
ing the cellular composition of the smear; the presence or character 
of inflammatory changes; the expected histopathologic change in the 
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squamous or squamous metaplastic cervical mucosa; and changes in 
columnar cells from the endocervical mucosa or an abnormality related 
to the endometrium. 
To evaluate the effectiveness of the screening programme, a 
population-based cancer registry was kept for all women with histolo-
gically diagnosed severe dysplasia, carcinoma in situ or invasive can-
cer of the cervix, and who resided in the area where the population 
screening was performed. Histological diagnoses and all pertinent per-
sonal data have been collected from the files of the pathology labora-
tories m the region since 1970. In this registry, lesions detected 
through the population screening, as well as lesions detected by gen-
eral practitioners and gynecologists with or without preceding cervical 
cytology, were recorded. The registration covers a period beginning 
6 years 7 months prior to the start of the population screening 
project (January 1, 1970 - July 31, 1976) as well as two complete 
screening rounds (August 1, 1976 - July 31, 1979 and August 1, 1979 
- July 31, 1982) and part of the third screening round (August 1, 
1982 - July 31, 1983). 
Results 
Participation 
During the f i rst screening period (August 1, 1976 - July 31 , 1979) 
87.911 women between the ages of 35 and 54 were invited for a 
smear. Of these, 64.903 (740o) participated. Of the non respondents, 
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12.854 (120o) had a smear taken by the i r own phys ic ian on the i r own 
in i t i a t i ve d u r i n g tha t same per iod 
D u r i n g the second screening (Augus t 1 , 1979 - Ju ly 3 1 , 1982) 88 678 
women from the same age group v\ere inv i ted and of these , 59.316 
(670o) pa r t i c i pa ted . In the same per iod another 11.667 (13*5)) women 
had a smear taken by t he i r own physic ian (Table 14) . The pe rcen tag -
es of smears made per age g roup decreased w i th increas ing age. 
Table 14: 
Number of women with at least one cervical smear during the first 
(August 1, 1976-July 31, 1979) and second (August 1, 1979-July 31, 
1982) screening cycles Ages 35-54 years 
Total number General practi- Percentage 
of women in Population tioners and with at least 
Period age group screening gynecologists one smear 
First 
screening 
cycle 87.911 64 903 (74) 12.854 (12%) 86 
Second 
screening 
cycle 88.678 59 316 (67) 11.667 (13%) 80 
Number of smears 
In t he en t i re reg is t ra t ion per iod (Augus t 1 , 1975 - J u l y 3 1 , 1982), 
107.956 women who had at least one cerv ica l smear t a k e n , were reg is -
t e r e d . Of these, 53.334 women had two smears, and 16.486 women had 
th ree smears, t a k e n . The number of severe abnormal i t ies detected in 
f i r s t , second, and t h i r d smears f rom the same woman is summarized in 
Tab le 15. 
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! Table 15· 
I Epithelial abnormalities consistent with severe dysplasia, carcinosa In situ, 
I or invasive cancer diagnosed during first, second, and third cytological 
I examination 
General practitioners 
Total Population screening and gynecologists 
Rank of Number of Number of Number of 
cyto- women with women with women with 
logical Number severe ab- Number severe ab- Number severe ab-
exami- of women normalities of women normalities of women normalities 
nation Ν N 0/00 Ν N 0/00 Ν N 0/00 
First 107.956 472 4.4 68.149 219 3.2 39 807 53 6.4 
Second 53.334 81 1.5 36.022 42 1.2 17.312 39 2.3 
Third lb 486 16 1.0 7 542 7 0.9 8.944 9 1.0 
At f i r s t screening, severe abnormalities were diagnosed m 472 (4.4 
0/00) smears. 
The percentage of abnormalities detected m smears made by general 
practitioners and gynecologists was higher. At the second screening, 
abnormalities, missed at f i rs t screening (prevalent cases) as well as 
those newly found (incident cases) were detected. The shorter the 
interval between the f i rst and second screening, the more likely the 
detected abnormality in the second smear implied a false negative or 
underestimated diagnosis at f i rs t screening. 
At second screening, the detection rate of severe abnormalities was 
much lower than at f i rs t screening (1 5 0/00). Again in smears made 
by general practitioners and gynecologists, more abnormalities were 
detected than m smears made at population screening. 
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The results at third screening permit an estimate of the incidence 
rate. In only 16 (1 .0 0/00) smears, a severe abnormality consistent 
with severe dysplasia and carcinoma m situ was detected. Detection 
rates in smears made at population screening and smears taken by 
general practitioners and gynecologists were comparable. 
Length of screening interval 
Within the population screening programme smears were made every 3 
years, but outside the programme the interval between smears var ied. 
The number of severe abnormalities in relation to the length of the 
screening interval is summarized in Table 16 
Table 16 
Cytological abnormalities consistent with severe dysplasia, carcinoma in 
situ, or invasive cancer in second smears in relation to length of the 
interval between two screenings 
Length of 
(months) 
<12 
12-36 
36-84 
Total 
interval Number of 
women 
5 881 
28.179 
13 588 
47 648 
Number with 
severe abnormalities 0/00 
10 1.7 
25 0.9 
16 1 2 
51 1 1 
This table shows that after one negative smear, only a few abnormali-
ties were diagnosed in successive smears, even after a screening 
interval from 36 to 84 months. The number of severe abnormalities 
was highest when the smear was made within 12 months. The advice 
for when to have a repeat smear taken after a negative smear at the 
population screening was 3 years, but gynecological complaints were 
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probably a reason to have a second smear taken earlier. The 
detection of severe abnormalities so soon after a negative smear indi-
cates a false negative cytological diagnosis at f i rs t screening. 
Cancer registry 
Carcinoma ¡n situ 
In the period prior to the start of the screening programme, carcino-
ma m situ was detected m 17.4 per 100.000 women m the age group 
35-54 years (Table 17 and Figure 9) . 
1
 Table 17· | Detection 
1 
Period of 
January 1 
August 1, 
August 1, 
August 1, 
rate of carcinoma in 
diagnosis 
1970-July 31, 1976 
li>76-July 31, 1979 
1979-July 31, 1982 
1982-July 31, 1983 
s i tu (100 
Age 
20-34 
4 7 
16 7 
2e 1 
21 3 
000/year: h i s to log ica l 
group (years) 
35-54 
17 4 
64 5 
45 6 
37 9 
55-89 
3 2 
6 7 
6 7 
8 3 
diagnosis) 
Total 
8 7 
30 3 
27.4 
23 4 
. 
During the f i rst screening round (August 1, 1976 - July 31, 1979) 
carcinoma in situ was detected with an increased frequency m 64.5 
per 100 000 women 
The detection rate declined in the second and th i rd screening cycles 
to 45 6 per 100 000 and 37.9 per 100 000 women, respectively These 
figures are still higher than the detection rate m the prescreenmg 
period. 
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Also in the women under age 35, carcinoma in situ was detected with 
an increased frequency after the start of the population screening 
programme. This t r e n d probably was due to an increased screening 
activity in th : s group by general practitioners and gynecologists. In 
the age group above 54 years, the detection rate doubled in the f i r s t 
screening round but remained almost constant after the start of the 
programme. 
Carcinoma In eltu erf cervix uteri 
r IO" 
70 
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Figure 9: Number of cases of carcinoma in situ of the cervix per 
100.000 women ages 35 to 54 in the region of Nijmegen, 
1970-1983 
Invasive carcinoma 
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Among women between the ages of 35 and 54, during the f i rst screen-
ing period (August 1, 1976 - July 31, 1979) a small increase occurred 
in the number of cervical cancers diagnosed, but during the second 
period (August 1, 1979 - July 31 , 1982) and the th i rd period (August 
1, 1982 - July 31, 1983), the detection rate showed a steep decline 
(Table 18 and Figure 10). 
Table 18: 
Invasive squamous carcinoma ine 
1 
I 
, Period of diagnosis 
! January 1, 1970-July 31. 1976 
1 August 1, 1976-July 31, 1979 
¡ August 1, 1979-July 31, 1982 
! August 1, 1982-July 31, 1983 
idence (100.000/year: 
Age 
20-34 
2.6 
2.9 
4.1 
5.1 
histological diagnosis) 
group (years) 
35-54 
18.6 
21.5 
9.0 
3.3 
55-89 
19.7 
18.2 
16.3 
8.3 
Total 
12.8 
13.4 
9.2 
5 4 
! 
Among women below age 35, invasive squamous cell cancer incidence 
showed a slight increase, but the number of cases is too small to 
warrant any conclusions. 
Among women over age 55, a small decline was visible during the sec-
ond screening cycle, but the incidence was much lower during the 
th i rd screening period (August 1, 1982 - July 31 , 1983). 
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Figure 10: Number of cases of invasive carcinoma of the cervix per 
100 000 women ages 35 to 54 m the region of Nijmegen, 
1970-1983 
Stage distribution 
The stages of the invasive squamous cancers (FIGO) (8) diagnosed m 
the period January 1, 1970 - July 31, 1983 are given in Table 19. 
Table 19 
D i s t r i b u t 
Per iod 
January : 
J u l y 3 1 , 
August 1 
J u l y 3 1 , 
August 1 
J u l y 3 1 , 
August 1 
J u l y 3 1 , 
ion of 
, 1970-
1976 
1976-
1979 
1979-
1982 
1982-
1983 
c l i n i c a l s t a g e s of 
N 
178 
96 
68 
13 
S t a g e 
un­
known 
11 
5 
2 
5 
Sub­
t o ­
t a a l 
167 
91 
66 
8 
c e r v i c a l 
C l l n i c a 
I A « ) 
20 
31 
21 
25 
c a n c e r s 
1 s t a g e 
IB(%) 
24 
17 
26 
25 
IIA(%) 
10 
10 
8 
13 
I I B W 
25 
23 
18 
13 
ь 
I I I « ) 
17 
17 
23 
--
IV(S) 
5 
3 
5 
-
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The distribution of the clinical stages shows that during the f i rs t 
cycle of the population screening programme (August 1, 1976 - July 
31 , 1979) compared with the period prior to the population screening, 
relatively more stage IA (microinvasive) tumors were diagnosed: 31% 
during the f i rst screening cycle compared with 20o during the period 
before screening. During the second cycle (August 1, 1979 - July 
31 , 1982) the stage distribution was quite different compared with the 
distribution during the f i rst screening cycle. The percentage of 
stage IA tumors diagnosed was 210o, which was much lower than the 
310o of stage IA tumors diagnosed during the f i rs t screening cycle. 
The percentages of tumors diagnosed m stages IB and I I I , (26% and 
23%) respectively, were much higher than the percentages of stage IB 
and III tumors (17% each) during the f i rst screening cycle. 
During the th i rd screening cycle, the number of invasive cervical 
cancers was very small, and for some patients, the stage is still 
unknown Therefore, these data should be considered only as an 
indicator of a possible change m stage distr ibut ion, with the 
necessity for longer follow up to confirm these preliminary findings 
Discussion 
In The Netherlands programme, the interval between cervical cytologi-
cal examination was 3 years. The results of this study show that 
there were only few epithelial abnormalities diagnosed after two neg-
ative smears. If we consider cytological abnormalities according to 
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the length of the screening interval, we see that even with a screen­
ing interval longer than 36 months only in 1 2 per 10 000 women was 
a severe epithelial abnormality diagnosed. The results from this and 
other screening programmes, together with the increasing evidence 
for a slow progression of the noninvasive precursors of cervical can­
cer, suggest that the interval between cytological screenings could be 
even longer without a significantly greater risk for the screened 
women participating in such programmes (3 9 ) . 
In an effort to restrict the effect of false negatives for the individual 
woman, it is advisable to make another smear soon after the the f i r s t 
one, e д . , after 1 year. After two negative smears, the screening 
interval should be longer, e . g . , 3 or even 5 years On a population 
level, this can greatly reduce the costs of the screening programme. 
The increased detection of carcinoma in situ in the f i r s t years of pop­
ulation screening cannot be the result of a real increase in incidence 
of the preclinical stages of cervical carcinoma. Carcinoma m situ is 
symptomless and the detection rate is associated with increased 
screening frequency. Unfortunately, exact information about the num­
bers of smears made before the population screening programme was 
started is lacking. Only accurate registration of the carcmomata in 
situ in the future can provide evidence for a real increase among 
women under 35 years of age. 
The decline in invasive squamous cancer incidence since 1979 among 
women ages 35 to 54 years can be explained by the detection of a 
higher number of carcmomata in situ during the f i rs t years of the 
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population screening programme. During that f i rs t screening cycle, 
the number of invasive cancers did not increase, but these were more 
often detected in a stage of micro invasion (stage IA; Table 20). 
Table 20. 
Distribution of clinical stages of cervical cancers m women ages 35-54 years 
Clinical stage 
ÏÏ >IB 
Stage Sub-
Period N unknown total N (%) N (%) 
January 1, 1970- 91 2 89 20 (22) 69 (78) 
July 31, 1976 
August 1, 1976- 37 3 34 5 (15) 29 (85) 
July 31, 1983* 
August 1, 1976- 40 2 38 22 (58) 15 (42) 
July 31, 1983** 
* Detected by gynecologist or general practitioner 
** Detected by population screening programme 
The incidence of invasive cancer among women ages 35-54 was below 
that among ages 20-34 However, absolute numbers are so small m the 
youngest age group (N=4 yearly) that dropping the age for starting 
screening to 25 does not seem justified m our country. 
In addition, invasive cancer incidence among women older than 54 
years, who were not included in the screening programme, showed a 
decline 6 years after the start of the programme, which can be 
explained by the increasing percentage of women, m this age group, 
who m former years, were eligible for population screening and hence 
received treatment when a preinvasive lesion was discovered. 
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Conclusion 
From the results of the study the conclusion can be drawn that popu-
lation screening has been succesful in our region. After two negative 
smears, in only 0.1OÓ of the screened women was a severe epithelial 
abnormality detected. 
The incidence rate of invasive cancer in the age group participating 
in the screening programme (35-54 years of age) dropped significantly 
3 years after the start of the programme. Six years later, the inci-
dence rate among women above age 54 also dropped considerably. 
The trend is not yet clear for women under 35, although an increase 
of severe epithelial abnormalities has occurred. The absolute numbers 
are stil l too small to warrant changing the screening policy to include 
younger age groups. However, the observed increase requires much 
attention in the years to come. The present screening programme 
involving women from 35 through 54 years of age, offers a succesful 
way to reduce greatly the morbidity from cervical cancer. 
Even a 5-year interval between screenings (following two negative 
cytological examinations) seems a sufficiently safe procedure for 
large-scale screening programmes. Such a frequency would greatly 
reduce the costs of population screening programmes. 
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CHAPTER 5A 
THE FALSE-NEGATIVE RATE IN CERVICAL 
CYTOLOGY* 
Yolanda van der Graaf MD and Peter G Vooijs MD, PhD 
Summary 
All women m Nijmegen, The Netherlands, with a histological diagnosis 
of severe dysplasia or carcinoma in situ or invasive carcinoma were 
investigated to see whether they had participated in a population 
screening programme. Within two years of diagnosis of a negative cer-
vical smear, 45 women were found to have histologically confirmed 
severe epithelial abnormality of the cervix From the same population 
as these apparently false negative cases, the number of t rue positive 
cases was available, and hence the sensitivity of cervical screening 
for severe dysplasia or carcinoma m situ and invasive carcinoma could 
be assessed. This was found to be 83o after 2 years. The laboratory 
procedures which led to the high sensitivity for the cervical cytodiag-
nosis were analysed. 
Experienced sample takers and cytotechnologists are very important 
and can reduce sample and screening errors . A good administrative 
system is necessary to guarantee proper follow up for women with 
abnormal findings in their cervical smears. 
*J Clin Pathology In Press 
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Introduction 
Over the past 30 years the false negative rate m cervical cytodiagno-
sis has been the subject of numerous studies. Estimates for the false 
negative rate range from 2 to 55° (1-10). For a long time the large 
number of false negative cytological diagnoses was a major obstacle to 
the acceptance and large scale implementation of cervical cancer 
screening programmes. 
In most studies only the screening history of women with invasive 
cancer of the cervix was reviewed To determine with maximal possi-
ble accuracy the sensitivity of the cytological diagnosis, however, the 
total number of women from the same population, m the same time 
period, who were cytologically tested and confirmed to have severe 
intraepithelial neoplasia or invasive cancers ("true positives") should 
be known as well Theoretically, histological examination of each cer-
vix examined cytologically would be neeaed to calculate the true sen-
si t iv i ty . As this is clearly impossible the sensitivity has to be esti-
mated in an indirect way. A feasible and acceptable procedure is to 
follow up all women with a negative cervical smear, provided the fo l -
low up is sufficiently long. 
In the Nijmegen population screening programme, during the years 
1976 to 1985 all women aged 35 to 55 were invited every three years 
for a cervical smear We had the opportunity to trace all women with 
negative cytology who subsequently developed a severe epithelial 
abnormality. 
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Methods 
Since 1976 a screening programme for cervical cancer for all women 
aged 35 to 55 years has been in progress in the city of Nijmegen and 
adjacent communitie in The Netherlands. The Nijmegen region com-
prises 735.000 inhabitants. About 88.000 women were invited to par-
ticipate. 
Smears were taken every three years. Overall attendance rates were 
740o and 67% in f i rs t and second screening respectively. 
A single cervical smear was taken with a slightly modified pointed 
Ayre's spatula. The specimens were obtained by trained sample tak-
ers. The smears were processed at the cytopathology laboratory of 
the department of pathology. University of Nijmegen and screened by 
experienced cytotechnologists. 
In cases of abnormal cytological findings the general practitioner was 
informed, who was then responsible for the follow up. If cytological 
findings were consistent with severe dysplasia, carcinoma in s i tu , or 
an invasive cancer referral to a gynecologist was recommended In 
cases of cytological diagnoses consistent with mild or moderate dyspla-
sia, the general practitioner was requested to take a repeat smear 
after six or three months, respectively The laboratory checked to 
see whether the advice had been followed, and if not, the general 
practitioner was again contacted. Cytology reports were graded as 
follows: grades I and I I , no or slight abnormalities; grade IMA, mild 
to moderate dysplasia; grade HIB and IV, severe dysplasia and carci-
noma in si tu, grade V, invasive cancer Mild dysplasia corresponds 
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with C INI , moderate dysplasia with CIN2, and severe dysplasia or 
carcinoma m situ with CIN3 (Table 21). 
. Table 21· 
Cytological d 
1 Papanicolaou 
! class 
I and II 
1
 IIIA 
1
 HIB, IV 
and V 
| Total 
lagnoses during the first 
Squamous epithelial 
changes consistent with 
-No epithelial 
abnormalities 
-Atypical squamous 
cells present 
-Atypical squamous 
metaplasia 
-Slight dysplasia 
-Moderate dysplasia 
-Severe dysplasia 
-Carcinoma in situ 
-Invasive cancer 
and second sc 
1st screen 
round 
62 039 
99 2*. 
324 
0 b% 
189 
0.3% 
62 552 
reening rounds 
ing 2nd screening 
round 
57 048 
98 9°; 
493 
0 9··. 
130 
0.2% 
57.671 
i 
To analyse the validity of the smear this classification was arranged 
into two categories Those smears of which the report recommended 
no further follow up (grades I and II) were considered to be negative 
and those smears for which the report requested an immediate repeat 
smear or a histological examination (grades HIB, IV, and V) were 
considered to be positive. Women with a diagnosis of mild or moder-
ate dysplasia were not included, because a follow up smear was 
advised within three to six months. To estimate the sensitivity of the 
cervical smear information has to be obtained on the number of true 
positive results and the number of false negative results. True posi-
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tive results are all positive smears for which a cytological diagnosis of 
severe dysplasia, carcinoma m si tu, or invasive cancer is confirmed 
by histological diagnosis in other words, the number of test positive 
results minus the false positive diagnoses. These data can easily be 
obtained from the follow up registration of the screening programme. 
The ratio between the number of true positive and test positive 
results is the predictive value of a positive test 
To calculate the number of false negative screening results we made 
use of a cancer registry. This registry was kept for all women with 
a tissue diagnosis of severe dysplasia, carcinoma in si tu, or invasive 
cancer of the cervix (11). Tissue diagnoses were obtained by histolo-
gical examination of biopsy specimens taken through a speculum, 
biopsies directed by colposcopy, or cervical curettmgs - sometimes, 
directly after a suspicious cytological result cone biopsy or hysterec-
tomy was performed In cases of more than one tissue analysis the 
most severe diagnosis was used for the calculation of the sensit ivity. 
The cancer registry was linked to the files of the screening pro-
gramme For those women with a tissue diagnosis of severe dysplasia, 
carcinoma in si tu, or invasive cancer who had participated in the 
screening programme, the cytological diagnosis of the smear, made up 
to 48 months before the tissue diagnosis, was recorded Sensitivity 
was then calculated m the usual way - as the ratio between the num-
ber of true positive results and the sum of true positive and false 
negative results. When the number of false negative results is 
known, specifity can be calculated as the ratio between the sum of 
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test negative and false positive results and the number of true neg-
ative results. 
Results 
Between 1976 and 1983 two three year screening rounds were complet-
ed. Participation rates were 74°o in the f i rs t screening round 
(1976-79) and 67% m the second (1979-82). In total, 120.223 smears 
were made (Table 21). Of these, 319 smears were classified as posi-
t ive and 119 087 smears as negative. In 817 women the cytological 
findings were consistent with a mild or moderate dysplasia. The follow 
up results of these women will be evaluated in a separate study. In 
20oo of women with a cytological diagnosis of moderate dysplasia severe 
abnormalities confirmed by histological examination were subsequently 
discovered. 
In 235 (740o) of the 319 women with positive results cytological f ind-
ings were confirmed by tissue diagnoses and were therefore regarded 
as true positive results In 76 smears (.24%) cytological diagnosis was 
not confirmed, and these smears were regarded as false positive 
results. In 32 of these, several repeat smears did not show any 
epithelial abnormalities. In 44 women histological examination was car-
ried out. In 18 women who had a hysterectomy and m 3 women who 
had a cone biopsy histology did not show severe abnormalities. In 16 
women two or more biopsies directed by colposcopy were obtained 
before the cytological result was regarded as false positive. In 2 
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women a blind biopsy, followed by negative smears, did not confirm 
the positive cytology In 5 women cervical curett ings, followed by 
negative smears did not confirm the positive cytology In 9 (3°) fol-
low up data were not available (Table 22). 
Table 22 
No of true positives results, false positives 
plus predictive value of positive diagnosis (S 
first and second screening rounds 
Test 
Screening round positive 
First 189 
Second 130 
Total 319 
Un-
known 
8 
1 
9 
True 
positive 
148 
87 
235 
and test positive results 
severe dysplasia) in 
False 
positive 
33 
43 
76 
Predictive 
value 
82% 
67% 
• 
From these data the predictive value of the positive test results could 
be computed by calculating the ratio between the number of true 
positives and test positives In the f i rs t period the predictive value 
was 820o, whereas in the second period it was 670o The value in the 
second period is lower because of the lower prevalence of epithelial 
abnormalities in the second period (Bayes' theorem (12)) 
Histologically confirmed cases of severe dysplasia, carcinoma in s i tu, 
and invasive cancer, diagnosed after a given interval after a cytologi-
cal smear had been diagnosed as negative, were considered to be 
missed positive results (Table 23). 
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Table 23: 
Interval in months between negative cytological 
dysplasia) and histological diagnosis of severe 
in situ or invasive cancer 
Histological diagnosis 
Severe dysplasia 
Carcinoma in situ 
Invasive cancer 
Total 
diagnosis (< slight 
dysplasia, carcinoma 
Interval in months since negative cyt 
diagnosis 
0-12 
1 
2 
2* 
5 
13-24 
3 
7 
11 
Clinical staging (FIGO) 
* Twice stage IIB; ** Stage IA; *** 
M * * Stage IIB and twice stage IV 
25-36 
5 
7 
2*** 
14 
37-48 
β 
4 
15 
Twice stage IB; 
>48 
4 
7 
11 
ological 
Total 
21 
27 
8 
56 
Sensitivity of cytological screening for the detection of these three 
epithelial abnormalities was calculated separately and as a group at 
24, 36 and 48 months of follow up (Table 24). 
Table 24: 
Sensitivity figures (%) calculated 
epithelial abnormalities, after 24, 
Epithelial abnormalities 
included in group of 
missed positives 
Histological diagnosis 
Severe dysplasia, 
carcinoma in situ, 
invasive carcinoma 
Carcinoma in situ, 
invasive carcinoma 
Invasive cancer 
for 
36 
different groups 
and 48 months 
Interval in months since a 
cytological diagnosis and 
diagnosis of severe epithe 
0-24 
94 
95 
99 
25-36 
89 
92 
98 
of Hissed 
negative 
listological 
liai abnormality 
37-48 
84 
89 
97 
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Sensitivity was relatively high when only invasive cancers were 
considered to be false-negative m the analysis of diagnosis after 24, 
36, and 48 months. Sensitivity figures were 99%, 980o, and 97o, 
respectively. 
A screening programme, however, should not only be directed 
towards the detection of invasive cancer but should also include the 
detection of severe epithelial abnormalities, which can be considered 
as potential precursors of cervical carcinoma. Sensitivity figures were 
therefore calculated for a broader spectrum of epithelial lesions than 
was the case m earlier reports. When all severe epithelial abnormali-
ties (severe dysplasia, carcinoma m si tu, and invasive cancers) diag-
nosed within 24, 36, and 48 months after a negative smear was made, 
were defined as false negative results, the sensitivity was calculated 
to be 940o, 89o, and 84%, respectively When only carcinoma in situ 
and invasive cancers were considered, sensitivity figures after 24, 
36, and 48 months were 95%, 92%, and 89%, respectively 
Discussion 
The estimates of sensitivity were high compared with those of previ-
ous reports. The estimate could have been biased because of three 
inaccuracies in the calculation of the false negative results. 
First ly, cases were included which became apparent during follow up, 
but which were still m a preclinical non detectable phase at the time 
when the negative cervical smear was made. Secondly, cases which 
page 96 Screening for cervical cancer 
were missed at the time of the cervical smear was taken but did not 
become evident during the time of follow up Third ly , m a number 
of women the epithelial abnormality might have regressed during the 
follow up 
The longer the follow up, the more cases will become evident, that 
were in a preclimcally non detectable phase at the time of the test 
and which cannot be distinguished from the t ru ly missed cases that 
became evident during the same follow up Day (13) suggested a 
method for calculating sensitivity that largely compensates for the 
inaccuracies mentioned above It is based on incidence rates alone 
For cervical cancer, this method is probably of limited value as inci-
dence rates in the absence of screening must be known, so it can 
only be applied when invasive cancers are defined as false negative 
results and not when preinvasive epithelial abnormalities are consid-
ered as well From our sensitivity figures it can be concluded that 
the quality of cervical screening is high compared with the results 
reported by others ( 1 2 4 8-10) Differences m screening methods 
and classification would not account for the differences in sensitivity 
Although the measures taken as part of the screening programme for 
quality control in the department of pathology, of this university are 
time consuming, they have been successful The smears in the popu-
lation screening project were made by experienced cytosmear takers. 
Some of them take more than 3 000 cervical smears every year The 
number of unsatisfactory smears and the number of smears without 
endocervical columnar cells is evaluated for each cytosmear taker and 
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compared with the results of the other samplers. When the number of 
unsatisfactory smears or the number of smears without endocervical 
columnar cells is too high, the reasons for the lower quality are anal-
ysed and new instructions are given (14-16). 
In this way sample error can be considerably reduced. 
Increasing sensitivity by taking two samples at a time, as has been 
suggested, was considered to be too expensive (7 17-20), because it 
increases screening time by about GOV and other measures to increase 
the quality of the smear were as effective. 
Follow up results were registered by the laboratory and if no follow 
up data became available the reasons for this delay were traced and 
the general practitioner was contacted. In the past the follow up of 
cases of mild, moderate, and severe epithelial abnormality has been 
monitored. This work task was time consuming but was very worth-
while as more then 90oo of the recommended follow up was completed. 
In cases of minimal changes and slight epithelial atypia the compliance 
with the advised follow up (a repeat smear after one year) was not 
checked by the laboratory. In only 270o of these cytological diagnoses 
was follow up spontaneously done. In fu ture, the follow up of these 
smears may have to be monitored by the laboratory as well, as these 
women have a considerably higher risk of developing cervical abnor-
malities (21). Other workers have noticed the problem of the incom-
plete follow up as well. Recently Elwood et al reported that of 1.062 
women with cytological diagnoses consistent with invasive cancer and 
other highly atypical and moderately atypical abnormalities, only 628 
(59%) had been followed up satisfactory (22). 
page 98 Screening for cervical cancer 
Ellman et al reported that of 100 women with invasive cancer of the 
cervix, 13 with a cytological diagnosis of suspected cervical cancer 
had not had adequate follow up (23) 
The smears were screened by experienced cytotechnologists, who 
examined smears from the population screening programme as well as 
those submitted by the hospital and family physicians. The daily 
workload was set at an average of 25 cases a day; quite a lot of time 
was spent on education All smears with false negative results and 
obviously underestimated diagnoses are rese reen ed and used for dis-
cussion by the whole group. 
In The Netherlands a cervical smear is recommended every three 
years for women aged 35 to 55. Our results show that tins policy 
works well. Many authors base the length of the recommended inter-
val on the high percentage of false negative smears in women with 
invasive carcinoma (6 24-27). We do not consider this to be a proper 
procedure It is well known that taking a satisfactory cervical smear 
from women with invasive carcinoma is more dif f icult because of the 
admixture of blood, necrotic material, cellular debris etc. (24 25). 
An epithelial abnormality may only be represented by a small number 
of abnormal cells and can easily be missed 
To reduce the problem of false negative diagnosis, quality control of 
the taking of the cytological sample and the cytological diagnostic 
procedure is important. To reduce the consequences of false negative 
results it may be advisable to make a repeat smear quite soon after 
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the initial smear for example, after one year. After two negative 
smears a longer interval of three years or even five years seems jus-
tified (28). The interval should be based on the total period entailed 
m the genesis of a cervical cancer and on the precursor lesions of 
invasive carcinoma. Some authors have calculated the average interval 
between mild, moderate, and severe dysplasia and carcinoma m situ to 
be 3 to 4 years (29 30). 
Using a three year interval, the possibility for the diagnosis of a 
preclinical non invasive epithelial abnormality is greatly increased, 
provided the quality of cervical cytology is well controlled and the 
series of cervical cytologic examinations is started within 5 years 
after the start of regular sexual contacts. 
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CHAPTER SB 
SCREENING ERRORS IN CERVICAL SCREENING* 
Yolanda van der Graaf MD, Peter G VOOIJS MD, PhD, F IAC, Hans U 
Gaillard MD, PhD, Daisy MDS Go MD, PhD 
Summary 
Five hundred and f i f ty five cervical smears, originally classified as 
Papanicolaou class I and II from women in whom three years later 
cytological findings consistent with moderate dysplasia, severe dyspla-
sia, carcinoma m situ or invasive cancer were diagnosed, were 
reviewed m oraer to estimate the screening error 
The initial diagnosis proved to be underestimated in 17 5% of the 
smears 
Introduction 
To be succesful a screening programme must be based on a reliable 
test A reliable test has a high sensitivity and, as important, a high 
specificity. Sensitivity is among people, who have a detectable pre-
clinical phase, the proportion positive to the screening test. "Posi-
t iv i ty" is disease. Specificity is among the people who do not have 
*Acta Cytologlca In Press 
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the detectable preclinical phase, the proportion negative to the test. 
"Negativity" is health (Table 25). 
Table 25 
Sensitivity 
Test outcome 
Pos itive 
Negative 
Sensitivity 
Specitivity 
and speci 
= a(a+c) 
= d(b+d) 
ficity of 
Ear 
Yes 
a 
с 
a 
iy 
screening 
disease 
No 
b 
d 
test 
If an epithelial abnormality is diagnosed m women who previously had 
a negative smear, there are two possibilities. First ly, the epithelial 
abnormality did not exist when the former negative smear was made 
Secondly, the epithelial abnormality did already exist, but was not 
recognized (screening or interpretation error) or was not present m 
the cell sample (sampling e r r o r ) . 
In this study we pay attention to the failures which are relatively 
easy to trace, the screening errors From 555 women with a cytologi­
cal diagnosis consistent with moderate dysplasia, severe dysplasia, 
carcinoma in situ or invasive cancer diagnosed with an interval of 
three years after a negative cytological smear, the negative smears 
were rescreened in order to estimate the screening error. If we 
assume that the preclinical detectable phase is about 15 years, it is 
likely that most severe epithelial lesions detected three years after a 
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negative smear were already present at the f irst screening. If the 
lesion cannot be detected after review of the slide, a sampling error 
is likely. In the l i terature, different estimates for screening errors 
are given. In studies, in which the value of taking two smears at the 
same time was assessed the screening error appeared to be about 6% 
( 1 - 4 ) . Information about the screening error can also be obtained 
from studies in which previously negative cytological smears were 
reviewed in women who developed invasive cancer (5 -10 ) . 
Methods 
In 1976 a population screening programme for cervical cancer was 
started in three pilot regions in The Netherlands, comprising the cit-
ies of Nijmegen, Rotterdam and Utrecht and their environs. In these 
selected regions approximately 4.5 million people are l iving. All women 
aged 35 through 54 were invited to participate; their names were 
obtained from city and local registries. Smears were taken every 
three years. Women were invited to come to a mobile van within their 
residential areas. A single cervical smear was taken with a slightly 
modified, pointed wooden Ayre spatula. The specimens were obtained 
by trained paramedical cytosmear collectors. The smears were pro-
cessed at the Cytopathology Laboratories of the Department of Pathol-
ogy, University of Nijmegen, Cyt-U-Universi ta i r in Utrecht and the 
Cytodiagnostic Foundation in Rotterdam. The smears were screened 
by experienced cytotechnologists. Cytological findings were recorded 
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m terms of the Papanicolaou classification to which a description of 
cytological findings m the smear was added. Each descriptive diag-
nosis comprised four terms indicating 1 the cellular composition of 
the smear 2. the presence or character of mf'ammatory changes 3. 
the expected histopathologic change m the squamous or squamous 
metaplastic cervical mucosa 4. changes in columnar cells from the 
endocervical mucosa or an abnormality related to the endometrium. 
For all women with a cytological diagnosis consistent with moderate 
dysplasia, severe dysplasia, carcinoma in situ or invasive cancer who 
had a negative cervical smear three years earlier, the f i rst smears 
were rescreened without knowledge of the f i rs t cytological diagnoses. 
The cytotechnologists were usually aware of the fact that rescreening 
of the smear was done because an abnormality had been found but 
they were not informed about the gravity of the diagnosis. 
During the f i rst and second screening approximately 800.000 women 
were invited for a smear Of these 71% participated in the f i rs t 
screening and 650o participated in the second screening. 165.185 
women were examined both m the f i rst and the second screening 
round with an interval of three years. Of these 802 (0.49%) had 
cytological diagnoses consistent with moderate dysplasia, severe dys-
plasia, carcinoma in situ or invasive cancer in the second smear 
(Table 26) 
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Table 26 
Distribut 
in the se 
Papanicol 
class 
I and 
IIIA 
ΠΙΑ 
HIB 
IV 
V 
Total 
II 
ion of cytomorphologic changes of the 
cond smear from women participating in 
aou Squamous epithelial changes 
No epithelial abnormality 
Atypical squamous cells present 
Atypical squamous metaplasia 
Slight dysplasia 
Moderate dysplasia 
Severe dysplasia 
Carcinoma in situ 
(Micro)invasive carcinoma 
cervical epithel 
the population 
N 
162 626 
1 757 
512 
192 
88 
10 
165 185 
lum found 
programme 
98 5 
0 1 
0 3 
0 1 
0 05 
0 006 
100 
At the f i rs t screening a diagnosis already consistent with slight or 
moderate dysplasia had been made on the smears of 247 women In a 
few women, even more severe epithelial abnormalities had been diag­
nosed at the f i rs t screening but those women had refused treatment 
In the cytological smears of the remaining 555 women, only minor 
abnormalities had been diagnosed at f i r s t screening Smears from 
these 555 women, of which the study group was composed, were res-
creeηed 
Results 
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The distribution of cytomorphologic findings of the cervical epithelium 
found at second screening three years later, is summarized in Table 
27. 
Table 27: 
Distribution of cyto 
from women at second 
the first smear (thr 
abnormalities were d 
Papanicol 
class 
ΠΙΑ 
HIB 
IV 
V 
Total 
aou 
Logical changes of the cervical epithelium in smears 
screening in the population screening programme. In 
ее years earlier) no abnormalities or only slight 
iagnosed 
Squamous epithelial changes N 
Moderate dysplasia 348 
Severe dysplasia 141 
Carcinoma in situ 58 
Invasive cancer 8 
555 
Of 
62.7 
25.4 
10.5 
1.4 
100 
In Table 28 the initial diagnosis of the f i rst smear is compared with 
the review diagnosis . In sixty eight smears (12.30o), it was con­
firmed that the smear did not contain atypical cells but that the 
material was too scanty or inadequate for a conclusive negative diag­
nosis. There was an exact correlation between the initial diagnosis 
and review diagnosis in 207 (37.30o) smears. But since differences 
between the cytological diagnoses: no epithelial atypia, atypical squa­
mous cells and atypical squamous metaplasia are only minimal and have 
no great clinical relevance, these diagnoses were also considered to 
be comparable (117 = 21.1%). 
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Table 28 
Comparison of initial di 
women in whose smears th 
consistent with moderate 
or invasive cancer 
agnosis and review 
cee years later cyt 
dysplasia, severe 
diagnosis First smears 
ological findings were 
dysplasia, carcinoma m 
from 
situ 
л 
Review No 
diagnosis epithelial 
abnormality 
Unsatisfactory 
No epithelial 
abnormality 
Atypical squamous 
cells present 
Atypical squamous 
metaplasia 
Slight dysplasia 
Moderate dysplasia 
Se\ere dysplasia 
Carcinoma in situ 
Total 
25 
80 
56 
19 
21 
19 
4 
2 
226 
Atypical Atypical 
squamous squamous 
cells present metaplasia 
42 
5 
107 
34 
59 
36 
7 
290 
1 
3 
20 
7 
7 
1 
39 
Total 
68 
85 
166 
73 
87 
62 
12 
2 
555 
V 
12.3 
15.3 
29 9 
13.2 
15 7 
11.2 
2 2 
100 
! 
For the smears with a diagnosis consistent with slight dysplasia, we 
considered the initial diagnosis underestimated if there was no epithe­
lial atypia detected in the f i r s t smear The sixty six smears with an 
initial diagnosis consistent with atypical squamous cells present and 
atypical squamous metaplasia and with a diagnosis consistent with 
slight dysplasia at second screening were not considered to be under­
estimated. Thus 390 (70.2o) smears were found to be correctly "neg­
ative" at f i rs t screening. The seventy of the epithelial abnormality 
was underestimated in 97 (17 5o) smears at f i r s t diagnosis. Of these 
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at review 21 (3 80o) were classif ied as consistent w i t h s l i g h t dysplas ia, 
62 (11 20o) as consistent w i t h moderate d y s p l a s i a , 12 (2 2o) as consis­
t e n t w i t h severe dysplasia and 2 (0 40o) as consistent w i t h carcinoma 
m s i t u . 
The resul ts of the review of cerv ica l smears, re lated to the c y t o l o g i ­
cal diagnosis of the second smear are summarized in Table 29. 
Table 29· 
Results of review of cervical smears 
related to cytological diagnosis of 
Review 
diagnosis 
of first 
smear 
Negative 
Undercalled 
Inadequate 
sampling 
Number of 
women 
Cyto logical 
Moderate 
dysplasia 
N 
279 
32 
37 
348 
/β 
80 
9 
11 
diagnosis 
, earlier reported as negative, 
second smear 
of the second 
Severe Carcinoma 
dysplasia in situ 
N 
80 
37 
24 
141 
* 
*« 
57 
26 
17 
N S 
28 48 
25 43 
5 9 
58 
smear 
Invasive 
cancer 
N % 
3 38 
3 38 
2 25 
8 
Total 
N 5 
390 70 
97 17 
68 12 
555 
From the women who had at second screening a cyto logical diagnosis 
consistent w i t h moderate d y s p l a s i a , 32 (9%) of t h e in i t ia l smears 
seemed to be u n d e r e s t i m a t e d . In women w i t h severe dysplasia th is was 
37 (260o) and in women w i t h a f ina l cytological diagnosis consistent 
w i t h carcinoma m situ t h i s was 25 (43co) In women w i t h a cytological 
diagnosis suspicious f o r invasive cancer at second s c r e e n i n g , at 
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review two (25o) of the initial smears were considered as unsatisfacto­
ry for cytological diagnosis and three (380o) smears were considerably 
undercalled. The presence or absence of endocervical columnar cells 
in the f i rs t smear was not related to the number of underestimated 
smears. In the region of Nijmegen and Utrecht, follow up could be 
traced for 278 women of the study group. 430o of the women with 
undercalled diagnoses at f i rst screening had histologically proven 
diagnoses of severe dysplasia, carcinoma m situ or invasive cancer 
after the second screening. For the women whose f i r s t smears were 
"correctly" screened 140o had a diagnosis of severe dysplasia, carcino­
ma m situ or invasive cancer after the second screening. For the 
women whose f i rst smears were inadequately sampled, 2ΤΌ had a diag­
nosis of severe dysplasia, carcinoma in situ or invasive cancer after 
the second screening. 
Discussion 
In this study smears with cytological diagnoses, no abnormalities, 
atypical squamous cells present and atypical squamous metaplasia 
(Papanicolaou classes I and II) were considered as "negatives" 
The high percentage (12,3o) of smears which at rescreening were 
found to be without atypical cells, but which were considered not 
reliable for cytological diagnoses because of being too scanty or 
because of admixture with blood and inflammatory cells was remarka­
ble. 
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In these women the sampling procedure was inadequate. The percent-
age of inadequate smears differed considerably in the three pilot 
regions. In one region it was only lo and in the other two 15o and 
160o respectively. 
This may be explained by differences m experience of the cytosmear 
takers and changing quality control procedures over the years m the 
laboratories caused by a "learning process". When population screen-
ing just started too many smears were considered as adequate while in 
fact they were not. It is known that in women with severe epithelial 
abnormalities more often the smear is inadequate (5-6 11-15). Eryth-
rocytes, inflammatory cells, cellular debris and necrotic material are 
responsible for this For this reason every inadequate smear is pres-
ently screened by two cytotechnologists. If the advice for a repeat 
smear is given the follow up of this advice should be controlled by 
the laboratory. 
In this study, the correlation between initial and review diagnosis was 
70oo, while 170o of the slides were underestimated. Comparison with 
other studies is diff icult as study populations and differences in ter-
minology can play an important role. 
In Table 30, results of some studies in which recent negative cytology 
m women developing invasive cancer was reviewed, are summarized 
(5-10 16). 
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Table 30: 
Review of recent cytology 
Author 
Berkely et al, 1980 (5) 
Berkowitz et al, 1979 (6) 
Gay et al, 1985 (16) 
Morell et al, 1982 (7) 
Paterson et al, 1984 (8) 
Rylander et al, 1977 (9) 
Walker et al, 1983 (10) 
in women 
N 
10 
15 
39 
17 
58 
64 
15 
develop 
Number 
of 
slides 
10 
10 
39 
36 
58 
56 
11 
ing invasive 
Review 
cervical 
results 
Positive/ 
suspicious 
5 
5 
13 
9 
34 
35 
3 
Nega-
tive 
3 
5 
26 
26 
13 
21 
5 
cancer 
Inade-
quate 
2 
1 
11 
3 
The screening error is high, but one should keep in mind that the 
review was not done blindly. Also in our study misinterpretation and 
inadequate sampling were present in 50% of the smears from women 
developing invasive cancers, but numbers are too small to warrant 
statistical analysis. 
Screening errors in studies in which the value of taking two samples 
at the same time was assessed, was about 5o (1-4). The most impor-
tant findings of these studies are summarized in Table 31. 
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Table 31. 
Screening and 
Author 
Beilby et al, 
(1) 1982 
Davis et al, 
(2) 1981 
Sedlis et al, 
(3) 1974 
Shulman et al 
(4) 1975 
sampling errors in paired sampling 
N 
Family planning clinic 1.352 
Referai clinic for women with 87 
abnormal cervical cytology 
Family planning clinic 17 737 
Family planning clinic 2 823 
Screening 
error 
7.4% 
5.8% 
5.0% 
small 
Sampling 
error 
11.1% 
10 9% 
30 0% 
21.0% 
In these studies review was done at the same time and bl ind. Cyto-
technologists m our laboratories knew that an abnormality was detect-
ed so it may have occured that they wanted to detect an abnormality 
m the former smear at review. Also reviewing took place three years 
later, and greater experience could play an important role. 
In our opinion quality control by the laboratory seems the best way 
to reduce screening and sampling errors. The quality of the sample 
can be controlled by the presence of endocervical columnar cells 
which is a reliable indicator of the quality (17-19). Taking duplicate 
smears can reduce the screening error but this measure seems too 
costly for large scale population screening programmes (3 4 20). Res-
creenmg of IO*?) of the slides is a quite unrewarding procedure. It 
may take years before an unreliable cytotechnologist is detected 
(21-22) Good supervision and training of cytotechnologists, a maxi-
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mum workload of 25-30 smears daily, and inter- and mtralaboratory 
exchanges of slides with abnormalities are effective ways to reduce 
screening errors 
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CHAPTER 6 
CERVICAL SCREENING REVISITED 
Yolanda van der Graaf MD, Gerhard A Zielhuis MSc, PhD, Peter G 
Vooijs MD, PhD 
Summary 
Cervical cancer screening has been practised for many years now, in 
some countries even for more than 25 years. However, only in latter 
years it has become evident that screening can be effective m reduc-
ing morbidity and mortality. Much of the evidence came from studies 
comparing the incidence rates of cervical cancer m regions prior to 
and after rapid introduction of screening, or between areas with dif-
ferent intensities of screening (1-4). Quite recently several case-
control studies about the effectiveness of cervical screening pro-
grammes, gave more valid support to the hypothesis that screening is 
effective m the prevention of invasive cancer of the uterine cervix 
and thereby increases life-expectancy (5-9). Although a randomised 
tr ial has not been performed and m view of the widespread screening 
activity is unlikely to be ever possible, there seems to be no doubt 
anymore about the potential beneficial effects of screening for cervical 
cancer. There has been disagreement on the overall effectiveness of 
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screening programmes and their most efficient and effective organiza-
tional setting This variation m opinion has resulted m differences 
in organizational approaches to screening programmes. In some coun-
tries screening is part of normal gynecological practice and women are 
encouraged to have a regular smear taken every year In other coun-
tries screening programmes are independent within the health servi-
ces, sometimes based on spontaneous participation, but more often 
nation-wide, centrally organized and population-based The IARC-
workmg-group on evaluation of cervical cancer screening programmes 
conducted a collaborative study of screening programmes in eight 
countries to estimate the risks of cervical cancer (10) There was 
little difference in the protection from screening every year compared 
to every three years Screening only once every 5 or 10 years 
offered appreciably less protection Centrally organized screening 
programmes were more effective than uncoordinated screening In 
The Netherlands a screening interval of 3 years was chosen In 
gynecological and general practice, however, it is quite common to 
take a cervical smear every year In the light of the results of the 
above mentioned programmes and the results m our own pilot region 
screening every year seems unnecessary and possibly rebundant In 
our own programme we saw a strong decline in the number of severe 
epithelial abnormalities m women screened twice and three times with 
an interval of 3 years The number of severe epithelial abnormalities 
diagnosed in women who were screened for the f i rs t time was 3 8 per 
thousand smears, 1 0 per thousand in women who were screened twice 
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and 0.7 per thousand in women who were screened three times in the 
programme. In only two women who were screened twice with an 
interval of 3 years, microinvasive cancer was detected. In women who 
were screened three times no (micro)invasive cancer was detected. 
Some people base their advice for a yearly interval on the high false-
negative rate of cervical screening in women with invasive cancer 
(11-14). In our opinion one could better address the question of 
false-negatives by good quality control of the cytological sample and 
the cytological diagnostic procedure. To reduce the consequences of 
the false-negatives it would be advisable to set a "negative base-line" 
by taking a repeat smear one year after an initial "negative" smear. 
After two negative smears an interval of 3 years seems justi f ied. 
After two negative smears taken at a 3-year interval one could extend 
the interval to 5 years. On a population level this procedure would 
greatly reduce costs and when centrally supervised would certainly be 
more or at least equally effective as present screening programmes. 
Another question concerns age groups eligible for screening. In The 
Netherlands population screening was directed to women aged 35 
through 54. This choice was made on basis of the distribution of 
average age of women with slight to moderate epithelial abnormalities 
of the cervix as well as on basis of the fact that under 35 few women 
have invasive cervical cancer or die from this disease. Screening a 
large number of women under 35 would have increased the cost of the 
screening programme in such a way that a screening interval of three 
years would have been impossible. After the introduction of the 
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organized screening programme also the number of smears made by 
general practitioner's and gynecologists increased, particularly m 
women below 35 the age group not eligible for screening. As a con-
sequence the datection rate of carcinoma m situ m these women 
increased but the incidence of invasive cancers under age 35 remained 
relatively small Absolute numbers are small m young women However 
considering the large number of carcinoma m situ m the age group 
30-34 it could be considered when means are available, to include also 
these women m the organized screening programme as well Inclusion 
of women under 30 will lead to the diagnosis of numerous possible 
precursor lesions, many of them will probably regress. 
Based on present evidence the conclusion that cervical screening can 
be effective is justified but only if some specific conditions are met 
Firstly, the compliance rate has to be high to cover also women at 
higher risk Known risk factors for disease, like for example sexual 
behaviour cannot be easily used to trace high risk women. 
Secondly, the quality of the sample and the cytodiagnosis should be 
high, thus reducing the number of false-negative diagnoses. Recent-
ly in several studies the presence of endocervical columnar cells in 
smears is proven to be of great importance (15-16). The number of 
epithelial abnormalities diagnosed in smears containing endocervical 
columnar cells is much higher than in smears containing only squa-
mous metaplastic cells and/or squamous cells. A smear without endo-
cervical columnar cells requires a more careful screening since an 
epithelial abnormality may only be represented by a small number of 
abnormal cells in these less satisfactory smears. 
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Third ly, proper follow up should be guaranteed. Apart from a good 
administration and registration, control of the given advices e.g. for 
a repeat smear or a referral for the gynecologist should be done. It 
seems reasonable to delegate this task to the laboratories. 
Fourthly, the treatment for the disease should be adequate. Besides 
the gam m life expectancy as positive effect of screening one should 
mention the decline in morbidity due to cervical cancer. Women with 
invasive cervical cancer, diagnosed after the introduction of cervical 
cancer screening programmes need less radical treatment. Population 
screening led in the Nijmegen region to a decrease in the number of 
invasive cancers and a shift to more favourable clinical stage d is t r i -
bution. Only for women with a stage IIB tumor survival improved m 
the course of years. Survival did not improve for each stage sepa-
rately (17). A dramatic improvement m the treatment of invasive 
cervical cancer does not seem likely in the next decade, which neces-
sitates continued detection of preinvasive lesions. 
On the other side of the balance are detrimental effects of screening 
and costs. Information on this subject is less conclusive and more 
subject to controversy. One major disadvantage of screening for cer-
vical cancer is the inclusion of non progressive cervical intraepithelial 
neoplasias in the search for cervical (pre)malignant changes. The 
natural history of intraepithelial neoplasia is so uncertain that pro-
gressive cases leading to invasive tumors cannot be distinguished 
from non progressive or regressive ones. This leads to "overdiagno-
sis" i.e. more diagnosed intraepithelial premahgnant lesions than m 
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fact actually exist This in turn leads to overtreatment When popu-
lation screening was introduced gynecologists were not prepared for a 
more expectant and conservative approach towards the epithelial 
abnormalities detected First ly, one has to question if a lesion should 
be treated Secondly, how it should be treated For less advanced 
premalignant lesions like slight and moderate dysplasia no immediate 
treatment seems necessary In view of the relatively large number of 
cases that will regress adequate cytological follow up supervised by 
the laboratory is necessary When an epithelial abnormality has been 
confirmed in a follow up smear colposcopie examination and a colpo-
scopically directed biopsy may confirm the non agressive character of 
the abnormality 
In principle all cases of severe dysplasia and carcinoma in situ should 
be treated as long as we do not have more precise knowledge about 
parameters that indicate the regressive or progressive character of 
the lesion Fortunately there is a growing awareness among gynecol-
ogists that conisations, formerly considered to be the treatment of 
choice for severe epithelial abnormalities, might be an overtreatment 
Ablatio of the abnormal mucosa should enable the pathologist to estab-
lish an accurate histological diagnosis of severe dysplasia and carcino-
ma m situ and at the same time therapeutic by removing the entire 
area of abnormal epithelium 
Especially m young women the regression rate of premalignant cervi-
cal neoplasia is high. Overdiagnosis and thus overtreatment are a 
threat for fert i l i ty These serious side-effects could be a reason to 
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abandon screening for this group because the positive effects, the 
detection of only a few women with invasive cancer do not balance the 
large number of unnecessary treated young women. 
Another disadvantage of screening is the relatively large number of 
false- positives. No one knows exactly to what extent women suffer 
from a false- positive diagnosis. The psychological effect is largely 
determined by the physician who discusses the diagnoses and the fol-
low up procedures to be taken. Furthermore it may largely depend on 
the kind of diagnostic follow up procedure which is carried out before 
the conclusion is drawn that it was a false-positive test result. In 
former days the test result was usually only proven to have been 
false-positive after a hysterectomy was performed. The introduction 
of colposcopy enables more selective diagnostic procedures, thus 
restricting the burden for the woman. Colposcopie examination can 
be performea if there is twice a cytoiogical diagnosis consistent with 
moderate dysplasia to exclude more severe epithelial lesions. There is 
no need to use colposcopy also after cytoiogical diagnosis of minor 
epithelial abnormalities, provided supervised follow up procedures 
have been agreed upon. The implementation of large scale screening 
programmes can only be acceptable provided screening is of high 
quality and when highly conservative and follow up procedures are 
agreed upon by all parties involved. The risk for women who partic-
ipate in screening programmes to be subjected to unnecessary proce-
dures would otherwise become too great. 
page 126 Screening for cervical cancer 
Well organized screening programmes are costly and represent invest-
ments in health which can be cashed m future only It may take 
10-18 years before cervical dysplasia becomes invasive. Detection of 
these lesions leads to treatment of a disease which would only become 
symptomatic after about 15 years Thus money is saved which would 
otherwise have to be spend 15 years later. With high quality screen-
ing and carefully executed follow up procedures m future there will 
be less hysterectomies, less radiotherapeutic treatment and less hospi-
tal expenses for malignant disease. 
In these considerations the question about the value of a woman's life 
has not been taken into consideration. This question cannot possibly 
be discussed m view of cost benefit ratio's. Centrally organized and 
well supervised screening, cautiously executed and in close coopera-
tion of all parties involved must be considered a cost effective 
approach to the problem of cervical cancer. Computer simulation 
models may be used to compare different screening policies in terms 
of their cost effectiveness (13-14) 
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SUMMARY 
In 1976 a population-based screening programme for cervical cancer 
started in the region of the city of Nijmegen, The Netherlands. All 
women aged 35 through 54 were invited to participate. Smears were 
taken every three years. 
Analysis of Dutch cervical mortality rates for the period 1936-1983 
showed a decline in the number of deaths due to cervical cancer 
(Chapter 1 ) . Neither cytological screening nor an increased rate of 
hysterectomies can be considered responsible for this decline; a fall 
in incidence because of better genital hygiene or an improvement of 
early diagnosis seems the most reasonable explanation. 
Improved therapy too could be an explanation for the mortality 
decline. Therefore survival rates for 359 women, diagnosed between 
1970 and 1985 with invasive cervical cancer, were computed (Chapter 
2 ) . Survival was dependent of age at diagnosis, extension of the 
tumor and year of diagnosis. To assess the effect of clinical stage, 
age and calendar time simultaneously we used the proportional hazards 
model according to Cox. Increasing age and increasing clinical stage 
gave a significant higher mortality. For stage IB and MA, however, 
there was no significant difference in survival . Only for women with a 
stage MB tumor survival improved in the course of years. 
Chapter 3 gives a summary of the results of the population screening 
programme in Nijmegen for the calendar period 1976-1985. The num-
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ber of severe histologically confirmed epithelial abnormalities found in 
women who were screened for the f irst time was 3 .8 per thousand 
smears, 1.0 per thousand in women who were screened twice and 0.7 
per thousand in women who were screened three times in the pro-
gramme. When considering the number of severe epithelial abnormali-
ties diagnosed in women who participated twice or three times in the 
screening programme it becomes evident that screening with a 3-year 
interval is effective in reducing the prevalence of severe epithelial 
lesions. 
The effectiveness of the screening programme was also established by 
means of a population-based case-control study (Chapter 4A) . The 
cervical smear history of 36 women with invasive cervical cancer was 
compared to that of 116 age-matched controls, drawn from local regis-
t rar 's offices. Of the cases 47% were screened at least once, while of 
the controls this f igure was 68%. The relative risk of getting invasive 
cancer for women ever screened compared to women who were never 
screened after correcting for the most important confounder, age at 
f i rst intercourse, was 0.22 (95% confidence interval 0 .07 -0 .69 ) . 
When the lenght of the interval since the last smear was considered, 
the relative risk was 0.18 (95% confidence interval 0 .05-0.62) when 
the smear was made between 2 and 5 years ago and 0.30 (95% confi-
dence interval 0 .09-1.02) when this smear was made more than 5 
years ago. 
Furthermore the population screening programme led to a marked 
increase in the detected number of carcinoma in situ in f irst 
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screening period but this number decreased in second and third 
screening period (Chapter 4 B ) . The number of cases of squamous 
cell cancer increased slightly in the f irst screening period but once 
the population was screened the detection rate of invasive squamous 
cell cancer, in the group of women aged 35 through 54 decreased 
from 18.6 per 106 during the period prior to the screening to 9 .0 per 
10* after the f irst screening and 3.3 per 105 after the second screen-
ing. For the women above the age of 54 the incidence of invasive 
cancer was reduced with 58% after the second screening. The inci-
dence rates of invasive cancer in women below 35 showed no signif i-
cant t rend . 
The cervical smear seems to be a reliable test for detecting abnormali-
ties of the cervical epithelium (Chapter 5 ) . For all women with a t is -
sue diagnosis of severe dysplasia, carcinoma in situ or invasive can-
cer it was investigated whether they were screened in the population 
programme (Chapter 5 A ) . In two successive screening periods of 
three years each 120.223 smears were made. Within 48 months after a 
negative cervical smear 45 women were entered in the cancer registry 
with a histological diagnosis of a severe epithelial abnormality of the 
uterine cervix. On the basis of the number of true positives and false 
negatives the sensitivity of the cervical screening for the detection of 
severe dysplasia, carcinoma in situ and invasive cancer could be 
assessed as 83% after an interval of 48 months. This remarkable high 
sensitivity is probably for a great deal due to the intensive quality 
control of sampling and screening procedures. 
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To assess the number of screening errors 555 smears, originally clas-
sified as Papanicolaou class I and II from women in whom three years 
later cytological findings consistent with moderate dysplasia, severe 
dysplasia, carcinoma in situ or invasive cancer were diagnosed, were 
reviewed in order to estimate the screening error (Chapter 5B). The 
initial diagnosis proved to be underestimated in 17.5% of the smears. 
Positive and negative aspects of cervical screening are discussed in 
Chapter 6. It can be concluded that cervical screening is useful in 
preventive medicine provided that the compliance rate is high, the 
quality of the sample and the cytodiagnosis is high, proper follow up 
is guaranteed and the treatment is adequate. A different screening 
scheme is suggested to decrease the cost-benefit ratio. When means 
are available it could be considered to include the age group 30-34 as 
well. Inclusion of women under 30 will lead to overdiagnosis and thus 
overt reatment. 
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SAMENVATTING 
In 1976 werd in Nijmegen en omgeving begonnen met de uitvoering 
van het proef bevolkingsonderzoek naar baarmoederhalskanker. Alle 
vrouwen van 35 tot en met 55 jaar werden iedere drie jaar voor het 
laten maken van een uitstri jk uitgenodigd. 
Analyse van de sterfte aan baarmoederkanker in Nederland laat vanaf 
1960 een daling zien (Hoofdstuk 1 ) . 
Georganiseerde screening of een toename van het aantal 
hysterectomieen kunnen deze daling niet verk laren. Een daling van de 
incidentje door b .v . toegenomen hygiene of diagnose in een minder 
ver gevorderd stadium lijken meer aannemelijk als verklar ing voor 
deze daling. 
Een verbeterde therapie voor invasief cervixcarcinoom zou ook nog de 
daling van de sterfte kunnen verklaren. Om de rol van de therapie 
van invasief cervixcarcinoom in het gewijzigde sterftepatroon na te 
gaan werd van ruim 350 vrouwen, bij wie in de periode 1970-1985 een 
invasief plaveiselcelcarcinoom van de baarmoederhals werd vastgesteld, 
de overleving berekend (Hoofdstuk 2 ) . De overleving was afhankelijk 
van leeftijd bij diagnose, uitbreiding van de tumor en jaar van 
diagnose. Al deze factoren hangen echter met elkaar samen. Zo 
worden de kleinere tumoren vaker bij jonge vrouwen gediagnostiseerd 
en heeft screening geleid tot diagnose in een minder ver gevorderd 
stadium. Door gebruik te maken van het multivariate proportional 
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hazards model van Сок kon voor het schatten van de afzonderlijke 
bijdrage van deze factoren rekening worden gehouden met deze 
onderlinge samenhang. 
De mortaliteit was duidelijk afhankelijk van de leeftijd bij diagnose en 
de uitbreiding van de tumor. Er was echter geen verschil tussen 
stadium IB en MA. Alleen voor vrouwen in stadium UB kon, rekening 
houdend met de leeftijd bij diagnose, een verbetering van de 
overleving in de loop der jaren worden aangetoond. 
In hoofdstuk 3 wordt een korte beschrijving gegeven van de 
organisatie van het bevolkingsonderzoek in de proefregio Nijmegen en 
worden de belangrijkste resultaten besproken. Het aantal ernstige 
epitheelafwijkingen, vastgesteld bij vrouwen die twee of driemaal 
hebben deelgenomen aan het bevolkingsonderzoek, was duidelijk lager 
dan bij de vrouwen, die voor de eerste keer deelnamen. Bij vrouwen 
die voor de eerste maal deelnamen, werd bij 3 . 8 per 1000 vrouwen een 
histologisch ernstige epitheelafwijking vastgesteld. Bij vrouwen die 
voor de tweede maal met een screeningsinterval van 3 jaar werden 
uitgestreken, werden bij 1.0 per 1000 vrouwen en bij vrouwen die 
driemaal met een interval van 3 jaar in het bevolkingsonderzoek 
werden uitgestreken, werden nog slechts bij 0.7 per 1000 vrouwen 
ernstige epitheelafwijkingen vastgesteld. 
De effectiviteit van het bevolkingsonderzoek in de proefregio Nijmegen 
werd geschat met behulp van een patiënt-controle onderzoek 
(Hoofdstuk 4 A ) . Het uitstri jk verleden van 36 vrouwen met invasief 
cervixcarcinoom werd vergeleken met dat van 116 vrouwen zonder 
baarmoederhalskanker. De controles werden op leeftijd gematcht. 
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Van de vrouwen met mvasief plaveiselcelcarcmoom was 47% minstens 
eenmaal gescreend, terwij l dit percentage bij de controles 680o was De 
kans op mvasief plaveiselcelcarcmoom voor de vrouwen, die minstens 
eenmaal werden uitgestreken, vergeleken met vrouwen die nooit een 
uitstri jk hadden laten maken was na correctie voor de belangrijkste 
verstorende variabele, leefti jd, waarop het eerste sexuele contact 
plaatsvond, 0 22 (95o betrouwbaarheidsinterval 0 07-0 69) Als de 
lengte van het interval sedert de laatste uitstr i jk m de beschouwingen 
wordt betrokken, dan is de kans op mvasief carcmoom voor de 
vrouwen, die tussen 2 en 5 jaar geleden een uitstr i jk lieten maken 
0 18 (950o betrouwbaarheidsinterval 0 05-0 62) en voor de vrouwen die 
langer dan 5 jaar geleden een uitstr i jk lieten maken 0 30 (950o 
betrouwbaarheidsinterval 0 09-1 02) t o ν de vrouwen die nooit 
eerder werden uitgestreken 
Het bevolkingsonderzoek leidde tot een sterke stijging van het aantal 
gediagnostiseerde carcinomata m situ tijdens de eerste 
screemngsronde Dit aantal daalde m tweede en derde 
screemngspenode (Hoofdstuk 4B). 
Het aantal gediagnostiseerde gevallen van plaveiselcelcarcmoom steeg 
iets tijdens de eerste screemngspenode, maar nadat de populatie 
eenmaal gescreend was, daalde de incidentie van mvasief 
plaveiselcelcarcmoom bij de 35-54 jarige vrouwen van 18 6 per 10s 
tijdens de eerste screemngspenode naar 9 0 per 105 m tweede 
screemngspenode en 3 3 per 105 in derde screemngspenode BIJ de 
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vrouwen ouder dan 55 jaar daalde de mcidentie van mvasief 
plaveiselcelcarcinoom met 580o na de tweede screemngsperiode. BIJ de 
vrouwen onder de 35 kan nog geen duidelijke trend worden 
waargenomen. 
De uitstr i jk l i jkt een betrouwbare test voor het vaststellen van 
afwijkingen van de baarmoederhals (Hoofdstuk 5) . Van alle vrouwen 
met een histologische diagnose van ernstige dysplasie, carcinoma m 
situ of mvasief carcmoom werd nagegaan of eerder in het 
bevolkingsonderzoek een uitstr i jk werd gemaakt (Hoofdstuk 5A). 
In de eerste twee ronden van het bevolkingsonderzoek werden 120.223 
uitstri jken gemaakt. BIJ 45 vrouwen werd binnen vier jaar een 
ernstige epitheelafwijkmg van de baarmoederhals vastgesteld. 
Op basis van het aantal terecht positieven en fout-negatieven kan de 
sensitiviteit van het cytologisch onderzoek worden geschat op 83% 
indien een interval van 48 maanden wordt gekozen. Het l i jkt dat de 
intensieve kwaliteitscontrole van uitstr i jk en cytologische beoordeling 
verantwoordelijk zijn voor deze goede resultaten. Om een indruk te 
krijgen van het aantal beoordelingsfouten werden 555 uitstr i jken, 
aanvankelijk als met of slechts gering afwijkend beoordeeld, van 
vrouwen bij wie 3 jaar later cytologisch een matige dysplasie, ernstige 
dysplasie, carcinoma m situ of mvasief carcmoom werd vastgesteld, 
opnieuw beoordeeld. De gestelde diagnose bleek m 17.5% van de 
uitstri jken ondergewaardeerd (Hoofdstuk 5B). 
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Positieve en negatieve aspecten van screening worden besproken in 
hoofdstuk 6. Dit leidde tot de conclusie dat het bevolkingsonderzoek 
naar baarmoederhalskanker een nuttig onderdeel kan zijn van de 
preventieve geneeskunde mits aan een aantal voorwaarden voldaan is. 
Om een gunstiger kosten-effectiviteits ratio te bereiken wordt een 
alternatief screeningsschema voorgesteld. Gezien de aanzienlijke 
overdiagnose en dus overbehandeling l i jkt screening van vrouwen 
onder de 30 jaar niet aan te raden. 
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